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INTRODUCTION 
1-8 
 Oral drug delivery has been known for decades as the most widely used route of 
administration among all the routes. The reasons that the oral route achieved such 
popularity may be in part attributed to its ease of administration as well as the 
traditional belief. The oral controlled-release system shows a typical pattern of drug 
release in which the drug concentration is maintained in the therapeutic window for a 
prolonged period of time, thereby ensuring sustained therapeutic action shown in 
figure 1. There are certain conditions for which such a release pattern is not suitable 
that demand release of drug after a lag time. In other words, they require pulsatile 
drug delivery system (PDDS).
 
Pulsatile  systems  are  designed  in  a  manner  that  the drug is available at 
the site of action at the right time in the  right  amount. Pulsatile drug delivery 
systems (PDDS) have attracted attraction because of their multiple benefits over 
conventional dosage forms. Pulsatile  drug  delivery  system  is  defined  as  the  rapid  
and  transient  release  of  certain  amount  of  molecules  within  a  short  time  period  
immediately after predetermined off-release periods i.e. lag time
4
. These  systems  are  
designed  according  to  the circadian  rhythm  or  biological  clock  of  the  body.
3
 
 
 
 
 
 
Figure 1.Schematic Representation of Different Drug Delivery SystemsWhere 
(A) sigmoidalrelease after lag time (B) delayed release after lag time (C) 
sustained release after lag time (D) extended release without lag time.
2
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Chronobiology 
3 
 Choronobiology is the science concerned with the biological mechanism of the 
disease according to a time structure. “chrono” pertains to time and “biology” 
pertains to the study , or science, of life. 
Biological rhythms  
 Ultradian Rhythms 
Oscillationsof shorter duration are termed Ultradian Rhythms (more than one cysle 
per 24 hrs). E.g. 90 minutes sleep cycle.  
 Infradian Rhythms 
Oscoillations that are longer than 24hrs are termed as Infradian Rhythms (less than 
one cycle per 24hrs). E.g. Monthly Menstruation. 
 Circadian Rhythms 
The term “circardian”, coined by Franz halberg, comes from the Latin circa, 
“around”, and diem of dies, “day”, meaning literally “approximately one day”. Our 
body appears to be genetically programmed to function on roughly a 24-hour cycle 
Cycle of Circardian Rhythms 
  
 
 
 
 
 
                                   Figure 2. The Circadian Pattern of Diseases
4 
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Chronopharmacokinetics 
Chronopharmacokinetics involves study of temporal changes in drug 
absorption, distribution, metabolism and excretion. Pharmacokinetic parameters, 
which are conventionally considered to be constant in time, are influenced by 
different physiological functions displaying circadian rhythm. Circadian changes in 
gastric acid secretion, gastrointestinal motility, gastrointestinal blood flow, drug 
protein binding, liver enzyme activity, renal blood flow and urinary pH can play role 
in time dependent variation of drug plasma concentrations. 
Chronotherapeutics  
Chronotherapeutic is the discipline concerned with the delivery of drugs according to 
inherent activities of a disease over a certain period of time. It is becoming 
increasingly more evident that the specific time that patients take their medication 
may be even more significant than was recognized in the past.  
Benefits of these Technologies
5 
• Once daily dose resembling multiple daily doses by releasing drugs in discrete bursts. 
• Constant drug levels at the site of action and prevent the peak-valley fluctuations. 
• Chance of development of drug resistance and tolerance can be reduced. 
• Rate of release independent of pH, food and minimal potential for dose dumping. 
• Facility to produce combination dosage forms, ease of combining pellets with 
different compositions or release pattern. 
• Protection of mucosa from irritating drugs. 
• Delivery profile designed to compliment circadian patter.. 
• Drug loss by extensive first pass metabolism is prevented. 
• Reduced  dose  frequency,  dose  size  and  cost, which  ultimately  reduces  side  
effects  and  local irritation, thereby improving patient compliance.. 
Limitations 
 
• Multiple manufacturing steps.  
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• Homogenicity of the coated barrier is mandatory to assure the predictability of the lag 
time.   
• Rupture  time  cannot  be  always  adequately manipulated  as  it  depends  on  the 
physicochemical properties of the polymer.   
• Pulsatile delivery drugs are costly, raw material is not easily available.   
• Dosage form design requires highly educated professionals.   
• Technologies employed and the equipment used is complicated. 
Diseases  presently  targeted  for  chronopharmaceutical formulations  are  those  for  
which  there  are  enough scientific  backgrounds  to  justify  PDDS-  compared  to 
the conventional drug administration approach . They include:  hypercholesterolemia,  
asthma,  cancer, duodenal  ulcer,  arthritis,  diabetes,  neurological disorders,  
cardiovascular  diseases  (e.g.,  hypertension and  acute  myocardial  infarction)  and  
colonic  delivery
6
.  
On which cases or circumstance pulsatile drug delivery is used they are listed 
below
7
.  
1)  Chronopharmacotherapy of diseases whichshows circadian rhythms in their 
pathophysiology.  
2)  Avoiding the first pass metabolism, e.g. protein and peptides 
3)  For which the tolerance is rapidly exists,  
4)  For targeting specific site in intestine, e.g. colon,  
5)  For time programmed administration of hormone and drugs,  
6)  For drugs having the short half life
 
Diseases Requiring Pulsatile Drug Delivery 
8 
1.  Peptic ulcer: Acid secretion is high in the afternoon and at night.  
2.  Asthma: Precipitation of attacks during night or at early morning hour  
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3.  Cardiovascular diseases: BP is at its lowest during the sleep cycle and rises steeply 
during the early morning period.  
4.  Arthritis: Pain in the morning and more pain at night   
5.  Diabetes mellitus: Increase in the blood sugar level after meal   
6.  Attention deficit syndrome: Increase in DOPA level in afternoon 
Methodologies for Pulsatile Drug Delivery Systems
4 
1. Time Controlled Pulsatile Release 
A. Single Unit System 
- Capsular systems 
- Port systems 
- Delivery by series of stops 
- Delivery by solubility modulation 
- Delivery by reservoir systems with erodible or soluble barrier coatings 
B. Multiparticulate Systems 
- Pulsatile system based on rupturable coating 
- Time controlled explusion system 
- Pulsatile delivery by change in membrane permeability 
2. Stimuli Induced 
A. Thermo Responsive Pulsatile Release 
B. Chemical Stimuli Induced Pulsatile Release 
- Glucose responsive insulin release device 
- Inflammation induced pulsatile  release 
- Drug release from intelligent gel responding to antibody concentration 
- pH sensitive drug delivery system 
C. External Stimuli Pulsatile Release 
- Electro responsive pulsatile release  
- Micro electro mechanical systems 
- Magnectically induced pulsatile release 
3. Pulsatile Release Systems for Vaccine and Hormone Product 
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Classification of Pulsatile Drug Delivery Technologies Based on Route of 
Administration
6 
1. By Transdermal Route 
- Crystal reservoior technology 
2. By Oral Route 
- Pulsincap 
- Diffucaps 
- Egalet 
- Orbexa 
- Minitabs 
- Contin 
- SODAS 
- IODAS 
- IPDAS 
- Geomatrix 
- Pulsys 
 
TIME CONTROLLED PULSATILE RELEASE 
A.   Single Unit System 
             Capsular system 
A  general  system consists  of  an  insoluble  capsule  body  housing  a drug 
,soluble cap  and  a  plug.  The plug is removed after a predetermined lag time owing 
to swelling, erosion, or dissolution. Pulsincap was developed by R.R. Scherer 
International Corporation, Michigan, US
3
 is an example of such a system that is made 
up of a water-insoluble capsule body filled with drug formulation (Fig. 2). The body 
is closed at the open end with a swellable hydrogel plug.  Upon  contact with 
dissolution medium or gastro-intestinal fluids, the  plug  swells,  pushing  itself  out  
of  the  capsule after  a  lag  time.  This is followed by a rapid drug release.  The lag 
time can be controlled by manipulating the dimension and the position of the plug. 
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For water-insoluble drugs, a rapid release can be ensured by inclusion of effervescent 
agentsordisintegrants. The  plug  material  consists  of  insoluble  but permeable  and  
swellable  polymers  (e.g. polymethacrylates), erodible compressed polymers (e.g.  
hydroxypropylmethyl cellulose,  polyvinyl alcohol,  polyethylene  oxide),  congealed  
melted polymers  (e.g.  Saturated polyglycolated glycerides, glycerylmonooleate), 
and enzymatically controlled erodible polymer (e.g., pectin). These formulations were  
well  tolerated  in  animals  and  healthy volunteers,  and  there  were  no  reports  of 
gastro-intestinal irritation. However, there was a potential problem  of  variable  
gastric  residence  time,  which was  overcome  by  enteric  coating  the  system  to 
allow its dissolution only in the higher pH region of small intestine . 
 
 
 
 
 
 
 
 
 
 
 
 
                                    Figure 3.Pulsincap 
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Port System  
The  Port  system was developed  by  Therapeutic system  research  laboratory  
Ann  Arbor,  Michigan,  USA, This  system  consists  of  a  gelatin  capsule  coated  
with  a  semi  permeable  membrane (cellulose acetate). Inside the capsule is an 
insoluble plug, an osmotically active agent along with the drug formulation. (24). 
When  this  cap  comes  into  contact  with  GI  fluids,  water  diffuses across the semi 
permeable membrane, resulting in increased pressure inside that ejects the plug after a 
predetermined lag time. The lag time is controlled by the thickness of the coating. 
The system  was proposed to deliver methylphenidate  for  the  treatment  of  
attention  deficit hyperactivity  disorder  (ADHD)  in  school-age  children. 
Thissystem avoided second time dosing, which was beneficial for school children 
during daytime. 
Delivery by Series of Stops  
This system is described for implantable capsules. The  capsule contains  a  
drug  and  a  water-absorptive  osmotic engine that are placed in compartments 
separated by  a  movable  partition.  The pulsatile delivery is achieved by a series of 
stops along the inner wall of the capsule. These stops obstruct the movement of the 
partition but are overcome in succession as the osmotic pressure rises above a 
threshold level. The number  of  stops  and  the  longitudinal  placements of the stops 
along the length of the capsule dictate the  number  and  frequency  of  the  pulses,  
and  the configuration  of  the  partition  controls  the  pulse intensity.  
Delivery by Solubility Modulation  
Solubility modulator of system provides pulsed delivery of variety of drugs. 
The system was especially developed for delivery of salbutamol sulphate that 
contained sodium chloride as modulating agent. Amount of sodium chloride was less 
than the amount needed to maintain saturation in a fluid enters the osmotic device. 
The pulsed delivery is based on drug solubility. Solubility has solubility of 275mg/ml 
in water and 16mg/ml in saturated solution of sodium chloride, while sodium chloride 
has solubility of 321 mg/ml in water, and its saturation solubility is 320mg/ml. these 
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values show that the solubility of the drug is function of the modulator concentration, 
while the modulators solubility is largely independent of drug concentration. The 
modulating agent can be a solid organic acid, inorganic salt, or organic salt. Ratio of 
drug/modulator may be varied to control zero order release period and commence 
pulsed release. After the period of zero-order release, the drug is delivered as one 
large pulse. 
 Delivery by Reservoir Systems with Erodible (or) Soluble Barrier 
Coatings  
Most of the pulsatile delivery systems are reservoir devices coated with a barrier 
layer. This barrier erodes or dissolves after a specific lag period, and the drug is 
subsequently released rapidly from reservoir core. The lag time depends on the 
thickness of the coating layer.  
B. Multiparticulate System  
Pulsatile System Based on Rupturable Coating 
These systems depend on disintegration of the coat for the release of drug.The 
pressure needed for the rupture of the coating is achieved by effervescent excipients, 
swelling agents, osmotic pressure. 
Time Controlled Explosion System 
Multiparticulate system where drug is coated on non-pareil sugar seeds followed 
by a swellable layer and an insoluble top layer coating (Ueda et al., 1994). The 
swelling agents used include superdisintegrants like sodium carboxymethyl cellulose, 
sodium starch glycolateetc, and polymers like polyvinyl acetate, polyacrylic acid etc. 
Alternatively, effervescent system comprising a mixture of tartaric acid, citric acid 
and sodium bicarbonate may also be used. Upon ingress of water, the swellable layer 
expands, resulting in rupture of film with subsequent rapid drug release.  
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Pulsatile Delivery by Change in Membrane Permeability  
The permeability and water uptake of acrylic polymers with quaternary 
ammonium groups can be influenced by the presence of different counter-ions in the 
medium. Several delivery systems based on this ion exchange have been developed. 
STIMULI INDUCED 
  In these systems there is release of the drug after stimulation by any biological 
factor like temperature, or any other chemical stimuli. 
 
A. Thermo-Responsive Pulsatile Release 
 Thermo-responsive hydro gel systems have been developed for pulsatile release. In 
these systems the polymer undergoes swelling or deswelling phase in response to the 
temperature which modulate drug release in swollen state. 
  
B. Chemical Stimuli Induced Pulsatile Systems 
 Glucose Responsive Insulin Release Device  
Several systems have been developed which are able to respond to changes in glucose 
concentration. One such system includes pH sensitive hydrogel containing glucose 
oxidase immobilized in the hydrogel. When glucose concentration in the blood 
increase glucose oxidase converts glucose into gluconic acid which changes the pH of 
the system. This pH change induces swelling of the polymer which results in insulin 
release. Insulin by virtue of its action reduces blood glucose level and consequently 
gluconic acid level also gets decreased and system turns to the deswelling mode 
thereby decreasing the insulin release.  
Inflammation Induced Pulsatile Release Device 
Yui and co-workers focused on the inflammatory-induced hydroxyl radicals and 
designed drug delivery systems, which responded to the hydroxyl radicals and 
degraded in a limited manner.  
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Drugs Release from Intelligent Gels Responding to Antibody Concentration  
Special attention was given to antigen-antibody complex formation as the cross-
linking units on the gel, since such interactions are very specific. Utilizing the 
difference in association constants between polymerized antibody and naturally 
derived antibodies towards specific antigens, reversible gel swelling/deswelling and 
drug permeation changes occurs. 
pH sensitive drug delivery system  
This type of PDDS contains two components. The first is fast release type while the 
other is pulsed release which releases the drug in response to change in pH. In case of 
pH dependent system, advantage has been taken of the fact that there exists different 
pH environment at different part s of the gastrointestinal tract. By selecting the pH 
dependent polymers drug release at specific location can be obtained. Examples of 
pH dependent polymers include cellulose acetate phthalate, polyacrylates, and sodium 
carboxymethylcellulose. These polymers are used as enteric coating materials so as to 
provide release of drug in the small intestine. 
III. External Stimuli Pulsatile Release:    
This system was divided into three subparts and is discussed below.   
1.   Electro responsive pulsatile release   
Electrically responsive delivery systems are prepared from polyelectrolytes (polymers 
which contain relatively high concentration of ionisable groups along the backbone 
chain) and are thus, pH-responsive as well as electro-responsive. Examples of 
naturally occurring polymers include hyaluronic acid, chondroitin sulphate, agarose, 
carbomer, xanthan gum and calcium alginate. The synthetic polymers are generally 
acrylate and meth acrylate derivatives such as partially hydrolyzed polyacrylamide, 
polydimethylaminopropyl acrylamide. 
2.   Micro electro mechanical systems (MEMS)     
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A micro fabricated device has the ability to store and release multiple chemical 
substances on demand by a mechanism devoid of moving its parts. The digital 
capabilities of MEMS may allow greater temporal control over drug release 
compared to traditional polymer-based systems.  Another development in MEMS 
technology is the microchip. The microchip consists of an array of reservoirs that 
extend through an electrolyte-impermeable substrate. The prototype microchip is 
made of silicon and contains a number of drug reservoirs, each reservoir is sealed at 
one end by a thin gold membrane of material that serves as an anode in an 
electrochemical reaction and dissolves when an electric potential is applied to it in an 
electrolyte solution.  The reservoirs are filled with any combination of drug or drug 
mixtures in any form (i.e. solid, liquid or gel). When release is desired, an electric 
potential is applied between an anode membrane and a cathode, the gold membrane 
anode dissolves within 10- 20 seconds and allows the drug in the reservoir to be 
released. This electric potential causes oxidation of the anode material to form a 
soluble complex with the electrolytes which then dissolves allowing re lease of the 
drug. Complex release patterns (such as simultaneous constant and pulsatile release) 
can be achieved from the microchips. Microchip has the ability to control both release 
time and release rate.  
3.   Magnetically induced pulsatile release  
The use of an oscillating magnetic field to modulate the rates of drug release from 
polymer matrix was one of the old methodologies. Magnetic carriers receive their 
magnetic response to a magnetic field from incorporated materials such as Magnetite, 
Iron, Nickel, Cobalt etc. For biomedical applications, magnetic carriers must be 
water-based,biocompatible, non-toxic and non-immunogenic mechanistic approach 
based on magnetic attraction is the slowing down of oral drugs in the gastrointestinal 
system. This is possible by filling an additional magnetic component into capsules or 
tablets. The speed of travel through the stomach and intestines can then be slowed 
down at specific positions by an external magnet, thus changing the timing and/ or 
extent of drug absorption into stomach or intestines. 
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IV. Pulsatile Release Systems For Vaccine And Hormone Products   
Vaccines are traditionally administered as an initial shot of an antigen followed by 
repeated booster shots to produce protective immunity. The frequency of the booster 
shots, and hence the exact immunisation- schedule is antigen dependent. Also, co-
administration of vaccine adjuvant is often required to enhance the immune response 
to achieve protective immunity. PDDS offer the possibility of single-shot vaccines if 
initial booster release of the antigen can be achieved from one system in which timing 
of booster release is controlled. Vizcarra et al. found in nutritionally anoestrous cows, 
GnRadministered in pulses of 2 mg over 5 min every hour for 13 days produced a 
higher frequency of luteal activity by 13th day than cows given continuous infusions 
or pulses every 4 Hr.  
RAMIPRIL
11 
Ramipril is a potent ACE inhibitor used in the treatment of hypertensive 
disease. It is a highly lipophilic (log p octanol/water, 3.32) and poorly water soluble 
drug, with absolute bioavailability of 28-35% and half-life 2-4 hours
4
. It undergoes 
significant 'first pass' metabolism. Ramipril is a prodrug and is converted into an 
active metabolite ramiprilat by liver esterase enzymes. Ramiprilat is 
mostly excreted by the kidneys. The half-life of ramiprilate is variable, and is 
prolonged by heart and liver failure, as well as kidney failure. 
Ramipril is marketed in India under the brand names of Cardace, Zigpril and 
Zorem. Single doses of Ramipril of 2.5 - 20 mg produce approximately 60 - 80 % 
inhibition of ACE activity 4hours after dosing with approximately 40 - 60% 
inhibition after 24 hours. 
MICROSPHERES
9-11 
Oral drug delivery has been known for decades as the most widely used route 
of administration among all the routes. The reasons that the oral route achieved such 
popularity may be in part attributed to its ease of administration as well as the 
traditional belief
1
.  
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Drug delivery systems (DDS) that can precisely control the release rates or 
target drugs to a specific  body  site  have  had  an  enormous  impact  on  the  health  
care  system. The ideal drug delivery system delivers drug at rate decided by the need 
of the body throughout the period of treatment and it provides the active entity solely 
to the site of action. So, carrier technology offers an intelligent approach for drug 
delivery by coupling the drug to a carrier particle such as microspheres, nanoparticles, 
liposomes, etcwhich modulates the release and absorption characteristics of the drug. 
 Types of drug delivery system are, 
 LIPOSOME  
 NIOSOME  
 NANOPARTICAL  
 MICROSPHERE   
 
MICROSPHERES 
There are various approaches in delivering a therapeutic substance to the 
target site in a sustained controlled release fashion. One such approach is using 
microspheres as carries for drugs. Microspheres are characteristically free flowing 
powders consisting of proteins or synthetic polymers which are biodegradable in 
nature and ideally having a particle size less than 200 µm
9
 
Microspheres used usually are polymers. They are classified into two type
9
 
1. Synthetic Polymers 
a. Non-biodegradable polymers 
e.g. Polymethacrylayte, Acrolein, glycidylmethacrylate,epoxypolymers 
b. Biodegradable polymers 
e.g. Lactides, Glycolides and their co polymers poly alkyl cyano acrylates, poly 
anhydride 
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2. Natural Polymers 
a. Proteins : Albumin , Gelatin And Collagen 
b. Carbohydrates : Agarose, Carrageenan , Chitosan, Starch 
c. Chemical Modified Carbohydrates:Polydextran,Polystarch. 
ADVANTAGES  
1. Microspheres provide constant and prolonged therapeutic effect.  
2. Reduces the dosing frequency and thereby improve the patient compliance.  
3. They could be injected into the body due to the spherical shape and smaller size.  
4. Better  drug  utilization  will  improve  the bioavailability  and  reduce  the  
incidence  or intensity of adverse effects.  
5.  Microsphere morphology allows a controllable variability in degradation and drug 
release. 
LIMITATION  
1. The modified release from the formulations.  
2.  The  release  rate  of  the  controlled  release dosage  form  may  vary  from  a 
variety  of factors like food and the rate of transit though gut.  
3. Differences in the release rate from one dose to another.  
4.  Controlled  release  formulations  generally contain  a  higher  drug  load  and  thus  
any  loss of integrity of the  release characteristics of the dosage form may lead to 
potential toxicity.  
5.  Dosage forms of this kind should not be crushed or chewed. 
TYPES OF MICROSPHERES  
 Bioadhesive microspheres 
 Magnetic microspheres 
 Floating microspheres 
 Radioactive microspheres 
 Mucoadhesive microspheres 
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 Polymeric microspheres 
BioadhesiveMicrospheres 
 The term “bioadhesion” describes materials that bind to biological substrates, such 
as mucosal members. Adhesion of Bioadhesive drug delivery devices to the mucosal 
tissue offers the possibility of creating an intimate and prolonged contact at the site of 
administration. This prolonged residence time can result in enhanced absorption and 
in combination with a controlled release of drug also improved patient compliance by 
reducing the frequency of administration. 
Magnetic Microspheres 
 This kind of delivery system is very much important which localizes the drug to 
the disease site. In this large amount of freely circulating drug can be replaced by 
smaller amount of magenetically targeted drug. Magnetic carriers receive magnetic 
responses to a magnetic field from incorporated materials that are used for magnetic 
microspheres are chitosan, dextran etc. The different type are Therapeutic magnetic 
microspheres are used to deliver chemotherapeutic agent to liver tumour. Drugs like 
protein and peptides can also be targeted through this system. 
Floating Microspheres 
 In floating types the bulk density is less than the gastric fluid and so remains 
buoyant in stomach without affecting gastric emptying rate. The drug is released 
slowly at the desired rate, if the system is floating on gastric content, increases gastric 
residence and fluctuation in plasma concentration. It also reduces chances of striking 
and dose dumping and produces prolonged therapeutic effect. 
Radioactive Microspheres 
 Radioactive microspheres deliver high radiation dose to the targeted areas without 
damaging the normal surrounding tissues. It differs from drug delivery, as radio 
activity is not released from microspheres but acts from within a radioisotope typical 
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distance and the different kinds of radioactive microspheres are α emitters, β emitters, 
γ emitters. 
Mucoadhesive Microspheres  
 Mucoadhesive  microspheres  which are of 1-1000nm in diameter and consisting 
either  entirely of a mucoadhesive polymer or having an outer coating of it and 
coupling of mucoadhesive properties to microspheres properties to microsphere has 
additional advantages, e.g. Efficient absorption and enhanced  bioavailability of the 
drugs due to a high surface to volume ratio, a much more intimate contact with the 
mucus layer, specific targeting of dug to the absorption site achieved by anchoring 
plant lectins, bacterial adhesion and antibodies, etc. on the surface of the 
microspheres.  
Polymeric Microspheres 
 The different types of polymeric microspheres can be classified as: 
 Biodegradable polymeric microspheres 
 Synthetic polymeric microspheres 
Biodegradable Polymeric Microspheres 
Biodegradable polymers prolongs the residence time when contact with 
mucosmembrane to its high degree of swelling property with aqueous medium, 
results gel formation. The rate and extent of drug release is controlled by 
concentration of polymer and the release pattern in a sustained manner. 
Synthetic Polymeric Microspheres 
The interest of synthetic  polymeric microspheres are widely used in clinical 
application, moreover that also used as bulking agent, fillers, embolic particle, drug 
delivery vechilesetc and proved to be safe and biocompatible. But the main 
disadvantage of these kinds of microspheres, are tend to migrate away from injection 
site and lead to potential risk, embolism and further organ damage.  
INTRODUCTION 
 
Department of Pharmaceutics Page 18 
 
ALBUMIN
12, 13 
 Albumin – natural protein is emerging as a versatile protein carrier for drug 
targeting and for improving the pharmacokinetic profile of peptide or protein-based 
drugs. Albumin is an acidic, very soluble protein that is extremely robust, it is stable 
in the pH range of 4-9, soluble in 40% ethanol, and can be heated at 60
0
c for up to 
10h without deleterious effects. Albumin microspheres are generally prepared by 
chemical cross linking or by addition of an organic solvent and stabilization at 
elevated temperatures. 
 Preparation of albumin microspheres can be done by suitable methods like: 
 Protein gelation technique  
 Single emulsion polymerization technique 
 Double emulsion polymerization technique 
 Multiple emulsion polymerization technique 
 Solvent evaporation technique 
 Sonication technique 
 Spray and freeze drying technique 
 Emulsification – heat stabilization technique 
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Protein Gelation Technique 
 
 
  
  
 
 
 
 
 
  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Dissolve egg albumin in distilled water 
Add drop wise into olive oil to make emulsion 
From the dropping funnel, emulsion was added drop wise into 
preheated olive oil (125±5). Stir at 1500 RPM 
After heat stabilization for 10 minutes the preparation was 
cooled to 25c. Centrifuge at 2500 RPM, decant the supernatant 
Wash the microspheres with liquid paraffin and twice with ether 
to obtain a free flowing and discreet product 
Suspend the microspheres in anhydrous ether, store at 4c in an 
air tight container 
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 Single Emulsion Polymerization Technique  
 
 
   
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Take 100ml of liquid paraffin oil in a glass beaker, mix with 
0.4% w/v span 60. Stir and heat at 70C until complete 
solubilisation 
Cool the mixture at room temperature 
Drop wise add 10ml of egg albumin aqueous solution of different drug 
to polymer ratio using a 22-gauge hypodermic syringe into an external 
phase. Stir light paraffin at 600 rpm for 10 minutes 
A w/o emulsion was formed. Raise the temperature of oil bath 
to 95c, stir until microspheres completely dehydrates 
Microspheres thus obtained were decanted, washed 6 times with 20ml 
petroleum ether for 2 minutes at 700 rpm. Finally wash 3 times with 60ml of 
distilled water for 2 minutes at 700 rpm, dry at room temperature for 24hr 
After drying, a fine yellow free flowing powder of 
microspheres was obtained that was stored indesicators at 
room temperature 
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Double Emulsion Polymerization Technique 
 A double emulsion is usually prepared in two main modes, 
  Mode 1: one step emulsification 
  Mode 2: two step emulsification 
      In one step emulsification mode a strong mechanical agitation is used for the 
water phase containing a hydrophilic surfactant and an oil phase containing large 
amounts of hydrophobic surfactant. Due to this a w/o emulsion is formed which 
quickly inverts to form a w/o/w double emulsion. 
   A two-step procedure is reported where the primary emulsion can be formed as a 
simple w/o emulsion which is prepared using water and oil solution with a low HLB 
(hydrophilic-lipophilic balance) surfactant. In the second step, the primary emulsion 
(w/o) is re-emulsified by aqueous solution with a high HLB surfactant to produce a 
w/o/w double emulsion. 
Multiple Emulsion Polymerization Technique 
 Multiple emulsion method involved formation of (o/w) primary emulsion (non-
aqueous drug solution in polymer solution) and then addition of primary emulsion to 
external oily phase to form o/w/o emulsion followed by either addition of 
crosslinking agent (glutataldehyde) and evaporation of organic solvent. This method 
of preparation is ideal for incorporating poorly aqueous soluble drug, thus enhancing 
its bioavailability. 
Solvent Evaporation Technique 
 This process is carried out in a liquid manufacturing vehicle. The albumin 
microspheres are dispersed in a volatile solvent, which is immiscible with the liquid 
manufacturing with the liquid manufacturing vehicle phase. A core material to be 
microencapsulated is dissolved or dispersed in the coating polymer solution. With 
agitation the coating material mixture is dispersed in the liquid manufacturing vehicle 
phase to obtain the appropriate size microsphere. The mixture is then heated if 
INTRODUCTION 
 
Department of Pharmaceutics Page 22 
 
necessary to evaporate the solvent. The solvent evaporation technique to produce 
microsphere is applicable to wide variety of core material. The core material either 
water soluble or water insoluble materials. Solvent evaporation involves the 
formation of an emulsion between polymer solution and an immiscible continuous 
phase whether aqueous (o/w) or non-aqueous. 
Sonication Technique 
 As the technique name itself is self-explanatory, it just involves a simple 
sonication for certain period of time till a desired size of albumin microspheres is 
obtained. The albumin solution of desired concentration is taken which is sonicated. 
To this add the drug which will then form intrachain cross-link with cysteine residues 
of albumin chains. 
Spray Drying Technique 
 In spray drying the polymer is first dissolved in a suitable volatile organic solvent 
such as dicholoromethane,acetone, etc. the drug in the solid form from is then 
dispersed in the polymer solution under high-speed homogenization. This dispersion 
is then atomized in a stream of hot air. The atomization leads to the formation of the 
small dropletsor the fine mist from which the solvent evaporate instantaneously 
leading formation of the microspheres in a size range 1-100µm. microparticles are 
separated from the hot air by means of the cyclone separator while the trace of the 
solvent is removed by vaccum drying. One of the major advantages of process is 
fessibility of operation under aseptic conditions. This process is rapid and leads to the 
formation of porous micro particles. 
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LITERATURE REVIEW 
Listair CR et al
14
.developed a chronopharmaceutical capsule drug delivery system 
capable of releasing drug after predetermined time delays. The drug formulation is 
sealed inside the capsule body by an erodible tablet. The release time is determined 
by erodible tablet erosion rate and increases as the content of an insoluble excipient 
(dibasic calcium phosphate) and of gel forming excipient (HPMC) increases. 
Programmable pulsatile release has been achieved from a capsule over a 2-12 hrs 
period, consistent with the demands of chronotherapeutic drug delivery system. 
Anil kumar et al
15
.developed and evaluated an oral pulsatile drug delivery system to 
mimic the circadian rhythm of the disease by releasing the drug with a distinct 
predetermined lag time of 5hrs(± 0.25hrs). The pulsincap formulation of metoprolol 
provides time controlled release to treat the nocturnal symptoms of hypertension and 
angina pectoris. Metoprolol succinate granules were prepared by wet granulation 
technique using a gugar gum polymer in different ratios. 
Viharmoturi et al
16
.developed and evaluated the modified pulsincap of an 
cardiovascular drug, Ramipril. Ramipril granules with different ratios of polymer 
plugs such as HPC(hydroxyl propyl cellulose), HPMC(hydroxyl propyl methyl 
cellulose k-15), and chitosan. The granules were prepared by wet granulation 
technique and evaluated for angle of repose, cars index, in vitro release, content 
uniformity. The modified pulsincap which contain HPC, Chitosan as polymer plugs 
had showed the required lad time, provided the immediate release of Ramipril and 
frequency of dosing is reduced.  
Hakan Eroglu et al
17
.formulated dexamethasone sodium phosphate (DSP) bovine 
serum albumin microspheres .microspheres were prepared by emulsion 
polymerization technique. An aqueous solution of gularaldehyde (25%w/v) was used 
as the crosslinking agent in two different amounts. The release time DSP was found 
to be extended in the series containing 15% DSP with the increase in the amount of 
glutaraldehyde used. Also it was observed that the release time is extended in series 
prepared using 0.5 ml glutaraldehyde with the amount of DSP. 
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Meena.A et al
18
. investigated the development of pulsatile drug delivery system 
based on an insoluble capsule body filled with lornoxicam microcapsules and sealed 
HPMCK4M plug. Optimized microcapsule formulations were selected by percentage 
drug content, invitro studies. Plug of varying thickness and hardness were prepared 
by direct compression which was then placed in the capsule opening. Pulsincap F2 
release was found to be diffusion controlled and followed zero order kinetics. 
Sukanya.M et al
19
.developed a pulsatile drug delivery system based on an insoluble 
capsule body filled with simvastatin microspheres and sealed with HPMCK4M plug. 
Microspheres were prepared by quasi emulsion solvent diffusion method of the 
spherical crystallization technique. Optimized microsphere formulation were selected 
by percentage drug content, invitro studies. The plug of varying thickness and 
hardness were prepared by direct compression which was then placed in the capsule 
opening. The drug release from all the pulsing caps followed zero order kinetics . 
Senthilnathan. B et al
20
. formulated and evaluated the pulsincap for anti diabetic dug 
Glibenclamide to control the increased blood glucose level after food consumption in 
diabetic patient by allowing the drug to release immediately after a lag time (after 
meals). Microsponges of different concentrations were prepared selected the best 
formulation for the development of pulsincap and the optimized microsponges were 
subjected to scanning electron microscopy, FT-iR , and in vitro studies.  
Najmuddin .M et al 
21
.developed and evaluated pulsatile drug delivery of 
flurbiprofen. The basic design consists of an insoluble hard gelatin capsule body, 
filled with eudragit microsphere of flubiprofen and sealed with a hydrogel plug. The 
entire device was enteric coated, so that the variability in gastric emptying time can 
be overcome and a colon-specific release can be achieved. Flurbiprofen microsphere 
was prepared by using ratio of Drug :Eudragit L-100 : Eudragit S-100 (1:1:2). 
Different hydrogel polymers were used as plugs (Guar gum, HPMC, Sodium 
alginate) to maintain a suitable lag period and it was found that the drug release was 
controlled by the proportion of polymers used. In vitro release studies of pulsatile 
device revealed that, increasing the hydrophilic polymer content resulted in delayed 
release of flurbiprofen from microsphere. Programmable pulsatile, colon-specific 
LITERATURE REVIEW 
 
Department of Pharmaceutics Page 25 
 
release has been achieved from a capsule device over a 2-15h period, consistent with 
the demands of chronotherapeutic drug delivery.  
Amol M et al
22
.designed and evaluated the pulsatile drug delivery system of Atenolol 
for chronomodulated therapy. Pulsatile release tablet comprises of a drug containing 
core and pH sensitive polymeric coating capable of delaying drug release and 
providing gastric resistance to overcome gastric emptying variability, thus allowing 
colon delivery to be pursued according to the time- dependent approach. To evaluate 
different pH sensitive polymers (Eudragit S-100, ethyl cellulose, sodium alginate) at 
different ratio in developing a suitable dosage form, exhibiting a no drug release in 
upper region of gastrointestinal tract (GIT) in order to provide site specificity as well 
as time controlled formulation. 
Sindhu Abraham et al
23
.studied the time dependent formulation named 'Modified 
Pulsincap' that would ensure chronotherapeutic delivery of Diclofenac sodium (DFS) 
in the colon for the relief of rheumatoid arthritis.Bodies of gelatin capsules were 
made insoluble by formaldehyde treatment. Drug loaded pellets were prepared by 
Extrusion-Spheronization technique. The pellets equivalent to 100mg of the drug 
were filled into the treated capsule shells, plugged with hydrogel polymers 
Hydroxypropyl Methylcellulose, Hydroxypropyl cellulose and Sodium Alginate at 
different concentrations and completely enteric coated with 5% Cellulose Acetate 
Phthalate. The ability of Modified Pulsincap to provide colon specific drug delivery 
was assessed by In vitro drug release studies in simulated gastric fluid for 2 hrs, 
simulated intestinal fluid for 3 hrs& simulated colonic fluid for 7 hours. The 
formulation was found to be intact for 2 hours in simulated gastric fluid. The 
accelerated stability studies carried out for three months as per ICH guidelines proved 
that the formulations were stable and thus Diclofenac Sodium could be successfully 
colon targeted with a time dependent formulation such as ‘Modified Pulsincap’.  
Masareddy R et at
24
.formulated and evaluated chronomodulatedpulsincap drug 
delivery system of Aceclofenac for arthritis. Aceclofenac microcapsules prepared by 
solvent evopration method using three different drug : polymer ratio (1:1, 1:2, 1:3) 
were subjected to various physic-chemical studies. The optimized formulation MC2 
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was filled into formaldehyde treated gelatin capsule using different concentrations 
(10%, 20% and 30%) of guar gum and methyl cellulose as hydrogel plugs. Further 
modified capsules were coated with Eudragit S-100 as enteric coating and HPMC as 
swellable coating by dip coat method. The prepared modified pulsincaps evaluated 
for physicochemical and release parameters. 
Howard NE Stevens et al
25
.evaluated the pulsincap to provide regional delivery to 
dofetilide to the human G tract. Dofetilife is a well absorbed drug, but showed a 
reduction in observed bioavailability when delivered from the pulsincap formulations, 
particularly at more distal GI tarct sites. Dispersion of the drug from the soluble 
excipient used and consistency of absorption from the colon was discussed. In these 
studies the effects of te degree of dispersion versus the site of dispersion could not be 
ascertained, nevertheless the scintigraphic analysis demonstrated  good in vitro- in 
vivo correlation for time of release from pulisncap preaprations. The combination of 
scintigraphic and pharmacokinetic analysis permits identification of the site of drug 
release from the dosage form and pharmacokinectic parameters to be studied in man 
in a non-invasive manner. 
Neha Manish Munot et al
26
.studied Modified Pulsincaps and compression coated 
tablets of aceclofenac, an steroidal anti-inflammatory drug used for the treatment of 
rheumatoid arthritis were developed to target drug release in the colon. Pulsincaps 
were formulated by treating bodies of hard gelatin capsules with formaldehyde and 
caps were untreated. Aceclofenac was incorporated into these specialized capsule 
bodies which were plugged with hydrogels like guargum, acacia, gelatin and sodium 
alginate separately and in combination. Pulsincaps were evaluated for lag time, 
qualitative test for free formaldehyde and in vitro drug release studies. Compression 
coated tablets of aceclofenac were developed using Guar gum to deliver drug to colon 
due to its release retarding property and susceptibility to microbial degradation by 
coloniclike Bacteroides species. These tablets were evaluated for various parameters 
like hardness, friability, drug content, in vitro drug release studies in simulated 
colonic fluid containing Male Wistar Rats colonic contents. The findings of the 
present study conclusively state that developed dosage forms are promising for colon 
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targeting of aceclofenac to synchronize the chronobiological symptoms for effective 
treatment of rheumatoid arthritis. 
Puttarajesh kumar et al
27
.formulated and evaluated pulsatile drug delivery system 
to achieve time release of Verapamil HCl. The basic design consists of an insoluble 
hard gelatin capsule body filled with physical mixture of Verapamil HCl with HPMC 
and Guar gum, lactose as channeling agent and sealed with a Sodium alginate and 
xanthan gum plug. The Verapamil HClpulsincaps were prepared by physical mixture 
method with lactose by varying drug to polymer ratio and evaluated for the 
micromeretic property, percentage yield, drug content, IR and in vitro release study. 
A hydrogel polymer Sodium alginate and Xanthan gum was used as plugs to maintain 
a suitable lag period. The in vitro release study were carried out using pH 1.2 buffer 
for a period of 2 h then 7.4 pH phosphate buffer for a period of 10 h. Formulation 
GS3 showing 94.5% drug release at 12 h with 3h lag time was selected as an 
optimized formulation. The programmable pulsatile release has been achieved from 
prepared formulation over a 12 h period, consistent with the demands of Pulsincap 
drug delivery. 
Srinivas L et al
28
.studied Ibuprofen as pulsincap technique. The prepared capsules 
were evaluated for uniformity of weight, drug content and in vitro release. Promising 
results indicated the usefulness of the pulsincap technique for controlled release of 
ibuprofen. 
LITERATURE REVIEW OF MICROSPHERES  
Dinalpatel et al
29
.formulated and evaluated the levosalbutamol sulphate loaded 
microspheres of chitosan and microspheres of Flax seed Mucilage in which both the 
polymers were checked as potential mucoadhesive agents and crosslinking was done 
with Glutaraldehyde , prepared by spray drying method, for prolonging drug release 
for asthma therapy.Microspheres having chitosan polymer : Drug ratio of 2:1 and 
0.6% of Glutaraldehyde and that of Flax seed Mucilage : Drug ratio of 3:1 and 0.9%  
of glutaraldehyde had food mucoadhesion ability. 
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AroraNeha et al
30
.evaluated the entrapment efficiency of glipizide microsphere. 
Glipizidemicrosphere was prepared by solvent evaporation technique using Eudragit 
RS 100 as a matrix polymer with dibutyl phthalate and diethyl phthalate as plasticizer 
and also without plasticizer. Increased in concentration of plasticizers the percentage 
entrapment efficiency of glipized was increased. Furthermore these microspheres can 
be orally administrated using capsule as a dosage form which will be ideal to 
maintain sustained release of glipizide.  
Senthil A et al
31
.investigated the design and characterization of mucoadhesive 
glipizide microsphere using carbopol 974 as polymer. Microspheres were prepared by 
simple emulsification phase separation technique using glutaraldehyde as a 
crosslinking agent. From twenty preliminary trail batches the optimized formulation 
was selected based on their percentage of mucoadhesion and sphericity of 
microspheres.3
2 
 full factorial design were employed. 
Mishra Manoj kumar et al
32
.prepared sustained-release ketorolac tromethamine 
microspheres of bovin serum albumin in different ratios by the emulsion cross-linking 
method using epichlorohdrin. The prepared microspheres were subjected to various 
physicochemical evaluation and in vitro release studies. The drug release from 
microspheres of 1:5 ratios is the most constant and prolonged drug release id 
diffusion followed by erosion. 
Vikas Parashar et al
33
.,developed biodegradable microspheres of Tinidazole using 
Bovine Serum Albumin. Four batches of Tinidazole microsphere were prepared by 
emulsion cross-linking method. The quantity of BSA varies for each formulation. 
Formulations were evaluated for particle size, Melting point, TLC, entrapment 
efficiency and in vitro release studies. The surface topography and internal textures of 
the microspheres was observed by scanning electron microscopy. The microspheres 
were spherical, discrete and compact and size distribution was between 33.28 to 
36.25 μm. In vitro studies were carried out at different pH for a period of 18 h and 
compared with marketed formulation. From all the batches it is concluded that when 
concentration of polymer increases microspheres shows more controlled and 
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prolonged release. The drug release was between 66, 51, 48, 42 (in %). The drug 
release from 1:4 is most prolonged and constant.  
AshviniUrs. V et al
34
.designed and formulated ketoprofen loaded albumin 
microspheres by solvent evaporation technique. The microspheres were found to have 
incorporation efficiency of 48% to 79%. The effect of albumin concentration was 
evaluated with respect to entrapment efficiency, particle size, surface characterization 
and in vitro release behaviours. From the preliminary trials it was concluded that it is 
possible to formulate sustained release ketoprofen loaded albumin microspheres.  
Aydan Gulsu et al
35
.developed albumin microspheres of ketoprofen were prepared 
by emulsion polymerization method using glutaraldehyde as cross linking agent. 
Optimal conditions were determined as 0.1mg/ml of albumin concentration, 
1000rpmstrring rate, 1% gultaraldehyde amount and 30 min crosslinking time. 
China Gangadhar B et al
36
.formulated and evaluated indomethacin microspheres 
using natural polymer, Egg albumin; semi synthetic polymer, Ethyl cellulose and 
synthetic polymer, meth acrylic acid esters (EudragitL 100) as the retardant materials. 
Microspheres were prepared by solvent evaporation method using an acetone / liquid 
paraffin system and Phase separation co-acervation method using petroleum ether and 
coconut oil as dispersion and continuous phase systems. The prepared microspheres 
were evaluated for their micromertic properties, drug content and encapsulation 
efficiency and characterized by Fourier transform infrared spectroscopy (FT-IR), and 
scanning electron microscopy (SEM) and in vitro release. The release of 
Indomethacin was influenced by the drug to polymer ratio and particle size &was 
found to be both diffusion and dissolution controlled. 
Sayyed Abolghas Semsajadi Tabassi et al
37
.prepared bovine serum albumin based 
microspheres bearing propranolol hydrochloride by emulsion-internal phase 
stabilization technique. The drug release from albumin microspheres was mainly 
controlled by diffusion. The total amount of drug released from microspheres after 
12h was 70%. In vitro experiments on the rat intestinal segments revealed that the 
microspheres could effectively pass their content through intestinal membrane. 
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Yamini Pendyala et al
38
.formulated and systemically evaluated in vitro and in vivo 
performance of mucoadhesive Ramipril microspheres for its potential use in the 
treatment of hypertension, myocardial infraction. Ramipril mucoadhesive 
microspheres , containing chitosan as mucoadhesive polymer and ethylcellulose as 
varrier polymer , were prepared by an emulsion-solvent evaporation technique.F4 
showed good dissolution profile with 81.0%.  
Dandagi PM et al 
39
.developed a bovine serum albumin (BSA) based microparticles 
bearing captropril were prepared by an emulsification-heat stabilization technique. 
The prepared microparticles were studied for drug loading, particle size distribution, 
in vitro release characterization, in vivo tissue distribution study and stability studies.  
LITERATURE REVIEW OF GRANULES 
Ravi S  Wanare et al
40
.enhanced dissolution rate of poorly water soluble drug by 
solid dispersion technique.  Ramipril  is  a  poorly  water  soluble  drug  and  it  also  
has  poor bioavailability. the  solid  dispersion  technique  was evaluated  for  
enhancement  of solubility  and  dissolution  rate. This study  investigated the  
feasibility  of  quaternary  solid  dispersion of  Ramipril  with  Poloxamer-188,  
HPMC  and PVP  K-30. The solid dispersions were characterized by FT-IR 
spectroscopy, differential scanning calorimetry and X-ray diffraction.  The  solubility  
and  dissolution  rate  of  solid  dispersions  were  compared  with  untreated 
Ramipril.  
Sudheer Nadendla et al
41
.Performed preparation and evaluation of floating tablets of 
Ramipril as model drug. For prolongation of gastric residence time floating 
effervescent  tablets were formulated  by various materials like hydroxypropyl 
methylcellulose  (HPMC)  K4M,  K 15M,  K100M  and micro crystalline cellulose 
and gas generating  agent  like sodium bicarbonate and evaluated for floating 
properties, swelling characteristics and drug release studies. In vitro drug release 
studies were performed and drug release kinetics evaluated using the linear regression 
method was found to follow   both the Higuchi and the Korsemeyer Peppas equation. 
The drug release mechanism was found non -fickian type in most of the formulations. 
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The developed floating tablets of Ramipril may be used in clinic for prolonged drug 
release for at least 12 h, thereby improving the bioavailability and patient compliance. 
Harish Chander  et al
42
.formulated and evaluated  fast  dissolving  tablets  of 
Ramipril using direct  compression  technique  (effervescent)  with  sodium  
bicarbonate,  mannitol, polyvinylpyrrolidone, citric acid. Eight different formulation 
of Ramipril were prepared by using different ratio of NAHCO:  MANNITOL by 
direct compression method.  The  hardness,  wetting  time,  water  absorption  ratio 
and  wetting  time ,in vitro release were  also  shows  the satisfactory  result. FDT4 
batch with sodium bicarbonate: mannitol (1:3) showed more release than the other 
concentration and better results.  
P Sivannarayana et al
43
.designed sustained release matrix tablets of Ramipril using 
tamarind kernels mucilage and evaluate the effect of polymer on release pattern of the 
drug. Ramipril sustained release matrix tablets were prepared by wet granulation 
method by using starch as granulating agent.  It  was  found  that  the  release  of  
drug  from  matrix  tablet  decrease  with  the increasing of percentage of polymer. 
Rajesh A et al
44
.worked to show the effect of various super disintegrates on the 
disintegration time and in vitro drug release rate on mouth dissolving tablets of 
ramipril. Disintegrating tablets are prepared by using different super disintegrants 
following wet granulation method. The Tablets were formulated by direct 
compression method, using Mannitol as diluent.  Crospovidone  (XL-PVP),  
croscarmellose  sodium  (Ac-Di-Sol®),  The Precompression parameters and post  
compression  parameters are performed.  The  optimized  formulation  was  selected  
based  on  the  results  and  stability  studies  were  carried  out  on  the optimized 
formulation and the percentage drug release was found to be 97.8%.  
Sachin Patil et al
45
.  Developed  a  stable  and optimized bilayer  tablet  having  
extended  release  (ER)  layer  of  Metoprolol  Succinate  which  is  a  Beta  blocker  
and immediate release(IR)  layer  of  Ramipril  which  is  an  ACE  inhibitor  and  
successfully  relievehypertention.  Eight batches of bilayer tablets were developed by 
Direct Compression technique. FTIR and DSC were carried out. It  was  found  that  
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the  in  vitro  drug  release  of  Metoprolol  Succinate  ER  was  best  explain  by  
Higuchi model.  Formulation  7  complied  with  all  the  USP  specifications  and  
thus  was  taken  as  stability  batch  successfully.  
Ratnaparkhi Mukesh et al
46
. Formulated and Evaluated Immediate Release Tablets 
of Metformin HCl and Glibenclemide Using Different Superdisintegrants  (Sodium 
Starch  Glycolate,  Croscarmellose,  Crospovidone  and polacrinpotasium)  and  by  
wet  granulation method.  The drug-excipients interaction  was  investigated  by  
FTIR.  The  granules  and  tablets  of metformin  and  glibenclamide  were  evaluated  
for  various  pre  and  post  compression  parameters.  Their results  were  found  that  
the in  vitro dissolution  studies  show  the  release  is  in  the  following  order  of 
superdisintegrants : Sodium Starch Glycolate >Crosspovidone>Polacrin potassium  
>Croscarmellose Sodium.  
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AIM AND PLAN OF WORK 
AIM OF THE WORK 
Angiotensin-converting enzyme (ACE) inhibitors are the first line drugs for the 
treatment of Hypertension. Ramipril is a prodrug belonging to the ACE inhibitor class of 
medication. It is metabolized to ramiprilat in liver and to lesser extent to kidney. 
Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the 
conversion of angiotensin I to angiotensin II. Angiotensin II regulated blood pressure and 
is a key component of the rennin-angiotensin –aldosterone system (RAAS). Ramipril is 
used in the treatment of hypertension, congestive heart failure, nephropathy, and 
myocardial infraction. 
The aim of the present study is 
 To formulate and evaluate Pulsatile drug delivery system of ramipril microspheres 
and granules providing chronomodulated therapy for the better treatment of 
hypertension. 
 To provide the drug at a time when it is needed most and dose related side effect could 
be minimized. 
PLAN OF WORK 
 Preformulation studies 
 Calibration curve for Ramipril 
 Preparation of Modified Pulsincap of Ramipril 
 Preparation of Immediate release granules 
 Preparation of cross-linked gelatin capsules 
 Preparation of Ramipril Microspheres 
 Preparation of polymer plug 
 Formulation of modified pulsincap 
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 Evaluation  
 Angle of repose 
 Compressibility index 
 Hausner’s ratio 
 Drug content uniformity 
 Test for formaldehyde treated empty capsules 
 Physiochemical characterization of hydrogel plug 
 Determination of swelling index of hydrogel plug 
 Particle size determination 
 Scanning Electron Microscopy (SEM) 
 Percentage yield  
 Drug loading capacity 
 In-vitro release of Ramipril IR 
 In-vitro release of Ramipril Microspheres 
 In-vitro release of Ramipril Pulsincap 
 Release kinetics of optimized formulation 
 Stability of optimized formulation as per ICH guidelines 
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RATIONALE OF THE STUDY 
The rational of this study was to design and evaluate an oral site specific pulsatile drug 
delivery system containing Ramipril which can be targeted in a time dependent manner to 
modulate the drug level in synchrony with the circardian rhythm of congestive heart failure. 
In this research work an attempt was made to develop a novel dosage form using a 
chronopharmaceutical approach. 
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor 
class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent in kidneys. 
Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion 
of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key 
component of the renin-angiotensin-aldosterone system (RAAS). 
RAMIPRIL IS SELECTED AS A MODEL DRUG FOR FOLLOWING 
REASONS 
 Mainly used for the relief from hypertension, congestive heart failure, 
nephropathy and myocardical infraction. 
 A shorter half-life (2-4hrs). 
 Poorly water soluble drug which undergoes first pass metabolism. 
 Absolute bioavailability of 28-35% 
RATIONALE FOR SELECTION OF CHRONOMODULATED DOSAGE 
FORM  
 Chronopharmacotherapy of diseases which show circadian rhythms in their 
pathophysiology.  
 Avoiding the first pass metabolism e.g. protein and peptides 
 For drugs which exhibit tolerance,  
 For targeting specific site in intestine e.g. colon,  
 For time programmed administration of hormone and drugs 
 For drugs having the short half life 
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DISEASE PROFILE
47 
Hypertension is the medical term for high blood pressure. It is known as the 
“silent killer”. Hypertension is high blood pressure. Blood pressure is the force of blood 
pushing against the walls of arteries as it flows through them. Arteries are the blood 
vessels that carry oxygenated blood from the heart to the blood’s tissues. 
Hypertension is the major health problem, because it has no symptoms. 
Hypertension is more common in men than women and in people over the age of 65 have 
hypertension. Hypertension is serious because people with the condition have a higher 
risk for heart disease and other medical problems than people with normal blood 
pressure. If left untreated, hypertension can lead to the following medical condition, 
arteriosclerosis (atherosclerosis), heart attack, stroke, enlarged heart, kidney damage. 
TYPES OF HYPERTENSION 
1. Essential Hypertension 
Most patients with hypertension have essential hypertension (also known as primary 
hypertension), with no identifiable cause for their disorder. 
2. Secondary Hypertension 
Patients with secondary hypertension have a specific identified cause for elevated BP. 
Although only 5% to 10% of those among the hypertensive population have secondary 
hypertension Secondary causes are potentially correctable. Further diagnostic workup 
also should be considered in patients who do not respond to increasing doses of 
antihypertensive medication or who have a sudden increase in BP or accelerated or 
malignant hypertension. A thorough review of prescription medications, nonprescription 
medications, and supplements should be conducted to rule out potential causes of BP 
elevations. 
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3. Pseudohypertension 
The possibility of pseudohypertension should be considered when measuring BP 
in elderly patients. In pseudohypertension, blood vessels become stiff and thick 
because of calcification and resist compression from the bladder of the inflatable BP 
cuff. Pseudohypertension is thought to be relatively rare. 
4. White-Coat Hypertension 
White-coat hypertension describes patients who have consistently elevated BP 
values measured in a clinical environment in the presence of a health care 
professional (e.g., physician's office), yet when measured elsewhere or with 24-hour 
ambulatory monitoring, BP is not elevated. 
Clinically Hypertension is classified based on the systolic and diastolic blood 
pressure given in table. 
Table 1 : Classification of Clinical Hypertension 
Blood pressure 
Classification 
Systolic (mmHg) Diastolic (mmHg) 
Normal <120 And<80 
Pre- hypertension 120-139 Or 80-90 
Stage 1 hypertension 140-159 Or 90-99 
Stage 2 hypertension ≥160 Or ≥100 
Isolated systolic 
hypertension 
≥140 <90 
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PATHOPHYSIOLOGY OF BP REGULATION 
Various neural and humoral factors are known to influence and regulate BP. 
These include the adrenergic nervous system (controls α- and β-receptors), the renin-
angiotensin-aldosterone system (RAAS) (regulates systemic and renal blood flow), 
renal function and renal blood flow (influences fluid and electrolyte balance), several 
hormonal factors (adrenal cortical hormones, vasopressin, thyroid hormone, insulin), 
and the vascular endothelium (regulates release of nitric oxide, bradykinin, 
prostacyclin, endothelin). BP is normally regulated by compensatory mechanisms 
that respond to changes in cardiac demand. An increase in cardiac output (CO) 
normally results in a compensatory decrease in total peripheral resistance (TPR); 
likewise, an increase in TPR results in a decrease in CO. 
The kidney plays an important role in the regulation of arterial pressure, 
especially through the RAAS. Decreases in BP and renal blood flow, volume 
depletion or decreased sodium concentration, and an activation of the sympathetic 
nervous system can all trigger an increased secretion of the enzyme renin from the 
cells of the juxtaglomerular apparatus in the kidney. Renin acts on angiotensinogen 
to catalyze the formation of angiotensin-1. Angiotensin-converting enzyme (ACE) 
converts angiotensin-1 to angiotensin-2. Angiotensin-2 is a potent vasoconstrictor 
that acts directly on arteriolar smooth muscle and also stimulates the production of 
aldosterone by the adrenal glands. Aldosterone causes sodium and water retention 
and the excretion of potassium. Several factors influence renin release, especially 
those that alter renal perfusion.  
Arterial BP also is regulated by the adrenergic nervous system, which causes 
contraction and relaxation of vascular smooth muscle. Stimulation of α-adrenergic 
receptors in the central nervous system (CNS) results in a reflex decrease in 
sympathetic outflow causing a decrease in BP. Stimulation of postsynaptic α1-
receptors in the periphery causes vasoconstriction. α-Receptors are regulated by a 
negative feedback system; as norepinephrine is released into the synaptic cleft and 
stimulates presynaptic α2-receptors, further norepinephrine release is inhibited. This 
negative feedback results in a balance between vasoconstriction and vasodilatation. 
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Stimulation of postsynaptic β1-receptors located in the myocardium causes an 
increase in heart rate and contractility, whereas stimulation of postsynaptic β2-
receptors in the arterioles and venules results in vasodilation. 
Epidemiologic evidence and clinical trials have demonstrated an inverse 
relationship between calcium and BP. Increased intracellular calcium concentrations 
can increase peripheral vascular resistance, resulting in increased BP. 
A decrease in potassium has been associated with an increase in peripheral 
vascular resistance.Insulin resistance and hyperinsulinemia also have been 
associated with hypertension. 
Angiotensin-2 promotes vasoconstriction of the vascular epithelium. Several 
other substances regulate vascular tone, however. Nitric oxide (NO) is produced in 
the endothelium and is a potent vasodilatory chemical that relaxes the vascular 
epithelium. The NO system has been firmly established as an important regulator of 
arterial BP. Hypothetically, some patients with hypertension have an intrinsic 
deficiency in NO release and inadequate vasodilation, which could contribute to 
hypertension and its vascular complications. 
FIRST-LINE AGENTS 
Angiotensin Converting Enzyme Inhibitors (ACEIs) 
The ACEIs directly inhibit angiotensin-converting enzyme and, therefore, 
block the conversion of angiotensin-1 to angiotensin-2. This action reduces 
angiotensin-2–mediated vasoconstriction and aldosterone secretion, and ultimately 
lowers BP. Because additional pathways exist for the formation of angiotensin-2, 
ACEIs do not completely block the production of angiotensin-2. These agents 
generally do not cause metabolic effects. Hyperkalemia is possible, however, and 
potassium concentrations should be monitored. Patients with chronic kidney disease 
or volume depletion may be more susceptible to hyperkalemia or to further kidney 
dysfunction. Bradykinin accumulates in some patients because inhibiting ACE 
prevents the breakdown and inactivation of bradykinin. Although this may lead to 
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additive vasodilation by releasing nitrous oxide, bradykinin can also cause a dry 
cough in some patients. Cough is the most frequent, yet harmless side effect of ACEI 
therapy. 
Angiotensin Receptor Blockers (ARBs) 
The newest antihypertensive agents are ARBs. They modulate the RAAS by 
directly blocking the angiotensin-2 type 1 receptor site. Therefore, they block 
angiotensin-2–mediated vasoconstriction and aldosterone release. Overall, ARBs are 
very well tolerated. They do not affect bradykinin and, therefore, do not cause a dry 
cough as do the ACEI. Because aldosterone is blocked, monitoring of potassium is 
important to avoid hyperkalemia. 
Calcium Channel Blockers (CCBs) 
The CCBs are pharmacologically complex. They reduce calcium entry into 
smooth muscles, cause coronary and peripheral vasodilation, and lower BP. All 
decrease cardiac contractility (except amlodipine and felodipine). Dihydropyridine 
CCBs are primarily vasodilators that can cause a reflex tachycardia. Non-
dihydropyridine CCBs (verapamil and diltiazem) directly block the AV node, 
decrease heart rate, decrease cardiac contraction, and have some vasodilatory effects. 
Side effects depend on the individual CCB used, but can include flushing, peripheral 
edema, tachycardia, bradycardia or heart block, and constipation. 
Thiazide Diuretics 
Diuretics, particularly thiazide diuretics, such as hydrochlorothiazide 
(HCTZ), have been extensively studied in large clinical trials for hypertension. 
When initially started, they induce a natriuresis that causes diuresis and decreases 
plasma volume. Diuresis usually decreases after chronic use with some of these 
agents, especially with thiazide diuretics. The long-term BP lowering effects are 
maintained because of a sustained decrease in peripheral vascular resistance (PVR). 
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SECOND-LINE AGENTS 
β-Blockers 
β-Blockers have several direct effects on the CV system. They can decrease 
cardiac contractility and output, lower heart rate, blunt sympathetic reflex with 
exercise, reduce central release of adrenergic substances, inhibit norepinephrine 
release peripherally, and decrease renin release from the kidney. All these contribute 
to their antihypertensive effects. Adverse metabolic effects include altered lipids and 
increased glucose concentrations. Similar to diuretics, these changes are generally 
temporary, however, and have minimal to no clinical significance. In primary 
prevention patients, they should be used as add-on therapy in combination with the 
other first-line agents (ACEI, ARB, CCB, or thiazide diuretic). 
Aldosterone Antagonists 
Spironolactone and eplerenone are aldosterone antagonists, also classified as 
potassium-sparing diuretics. Potent blockade of the aldosterone receptor inhibits 
sodium and water retention, and inhibits vasoconstriction. Hyperkalemia, a known 
dose-dependent effect. 
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DRUG PROFILE
48,51 
RAMIPRIL 
Category  
           Antihypertensive Agents, ACE (Angiotensin converting enzyme) inhibitors 
Physiochemical Properties  
                             Description         : A white or almost white, crystalline powder. 
                             Solubility  :  Freely soluble in Methanol, Sparingly soluble in  water 
                             CAS Number      :  87333-19-5 
                            Chemical Name :(2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(ethoxycarbonyl)-3-                    
phenylpropyl]amino]propanoyl] 
      Molecular Formula :  C23H32N2O5 
         Molecular Weight :  416.5106 
 
 
         Structural Formula :   
 
MECHANISM OF ACTION 
 Ramipril is a prodrug belonging to the ACE inhibitor class of medication. 
Ramiprilat, the principle active metabolite of ramipril, competitive inhibitor of 
Angiotensin converting enzyme, the enzyme responsible for the conversion of 
angiotensin I(ATI) to angiotensin II (ATII). AT II regulates blood pressure and is a 
key component of the rennin-angiotensin-aldosterone system (RAAS). Ramipril 
also causes an increase in plasma renin activity likely due to a loss of feedback 
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inhibition mediated by AT II on the release of renin and/or stimulation of reflex 
mechanisms via baroreceptors. 
PHARMACOKINETICS 
Absorption 
 The extent of absporption is at least 50-60%. Food decreases the rate of 
absorption from the GIT without affecting the extent of absorption. The absolute 
bioavailability of ramipril and ramiprilat were 28 and 44% respectively, when oral 
administration was compared to intravenous administration. 
Protein Binding  
 Protein binding of ramipril is about 73% and that of ramiprilat about 56% 
Half- life : 2-4 hrs  
CLINICAL APPLICATION 
 The indications are Hypertension ,Congestive heart failure, Myocardial infarction, 
Diabetic Nephropathy 
TOXICITY 
Symptoms of overdose may include excessive peripheral vasodilation (with 
marked hypotension and shock), bradycardia, electrolyte disturbances, and renal 
failure. The most likely adverse reactions are symptoms attributable to its blood-
pressure lowering effect. May cause headache, dizziness, asthenia, chest pain, 
nausea, peripheral edema, somnolence, impotence, rash, arthritis, and dyspnea. 
DOSAGE 
a) Initial – 2.5mg once daily increased to 5mg once daily after 1 week if tolerated. 
b) Maintenance – 10mg one daily after a further three week. 
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EXCIPIENTS PROFILE
 
ALBUMEN
50 
1. Nonproprietary Names 
BP: Albumin Solution 
PhEur: Human Albumin Solution 
USP: Albumin Human 
2. Synonyms 
Alba; Albuconn; Albuminar; albumin human solution; albumin 
humanisolutio; Albumisol; Albuspan; Albutein; Buminate; human serum albumin; 
normal human serum albumin; Octalbin; Plasbu-min; plasma albumin; Pro-Bumin ; 
Proserum; Zenalb. 
3. Chemical Name and CAS Registry Number 
Egg albumin [9006-59-1]  
4. Empirical Formula and Molecular Weight 
Human serum albumin has a molecular weight of about 66 500 andis a 
single polypeptide chain consisting of 585 amino acids. 
5. Functional Category 
Stabilizing agent; therapeutic agent. 
6. Applications in Pharmaceutical Formulation or Technology 
Albumin is primarily used as an excipient in parenteral pharmaceutical 
formulations, where it is used as a stabilizing agent for formulations containing 
proteins and enzymes.  
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Albumin has also been used to prepare microspheres and microcapsules for 
experimental drug-delivery systems. 
As a stabilizing agent, albumin has been employed in protein formulations 
at concentrations as low as 0.003%, although concentrations of 1–5% are 
commonly used. Albumin has also been used as a cosolvent for parenteral drugs, as 
a cryoprotectant during lyophilization, and to prevent adsorption of other proteins to 
surfaces. Therapeutically, albumin solutions have been used parenterally for plasma 
volume replacement and to treat severe acute albumin loss. However, the benefits 
of using albumin in such applications in critically ill patients have been questioned. 
7. Description 
 Albumin human as a sterile nonpyrogenic preparation of serum albumin obtained 
from healthy human donors; see Section 13. It is available as a solution containing 
4, 5, 20, or 25 g of serum albumin in 100 mL of solution, with not less than 96% of 
the total protein content as albumin. The solution contains no added antimicrobial 
preservative but may contain sodium acetyltryptophanate with or without sodium 
caprylate as a stabilizing agent. In the solid state, albumin appears as brownish 
amorphous lumps, scales, or powder. 
8. Solubility 
Freely soluble in dilute salt solutions and water. Aqueous solutions 
containing 40% w/v albumin can be readily prepared at pH 7.4. The high net charge 
of the peptide contributes to its solubility in aqueous media. The seven disulfide 
bridges contribute to its chemical and spatial conformation.  
9. Stability and Storage Conditions 
Albumin is a protein and is therefore susceptible to chemical degradation 
and denaturation by exposure to extremes of pH, high salt concentrations, heat, 
enzymes, organic solvents, and other chemical agents. Albumin solutions should be 
protected from light and stored at a temperature of 2–25 8 C or as indicated on the 
label. 
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HYDROXYL PROPYL METHYL CELLULOSE
50 
1. Non Proprietary Names 
BP :Hydromellose 
JP :  Hydroxyl propyl methyl cellulose 
PhEur :Hypomellosum 
USP- NF :Hypromellose 
2. Synonyms  
Benece, MHPC; E464; hydroxyl propyl methylcellulose; HPMC: Methocel; 
methylcellulose propylene glycol ether; methyl hydroxyl propyl cellulose; Metolose; 
Tylopur. 
3. Chemical Name  
Cellulose hydroxyl propyl methyl ether. 
4. CAS Registry Number 
     [9004-65-3] 
5. Molecular Formula 
    Approximately 10000-1500000. 
6. Functional Category 
Bioadhesive material, dissolution enhancer, controlled release agent, modified release 
agent, solubilizing agent, mucoadhesive, coating agent, film-former, rate-controlling 
controlling polymer for sustained release, stabilizing agent, suspending agent, tablet 
binder, viscosity- increasing agent. 
7. Applications in Pharmaceutical Formulation 
 Hypromelloseis widely used in oral, ophthalmic, nasal, and topical 
pharmaceutical formulations 
 Concentrations between 2% to 5% w/w may be used as a binder in either wet or 
dry granulation process. 
 High- viscosity grades may be used to retard the release of drugs from a matrix at 
levels of 10-80% w/w tablet and capsules. 
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 Hypromelloseis also used in liquid oral dosage forms as a suspending and/or 
thickening agent at concentrations ranging from 0.25-5.0% 
 
8. Description  
Hypromelloseis an odourless and tasteless, white or creamy-white fibrous or 
granular powder. 
9. Solubility  
Soluble in cold water, forming a viscous colloidal solution; practically insoluble in 
chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol and 
dichloromethane, mixtures of methonal and dichloromethane, and mixtures of water 
and alcohol. 
10. Incompatibility  
Incompatible with some oxidizing agents. Since it is non-toxic, hypromellose will 
not complex with metallic salts or ionic organincs to form insoluble precipitates.  
11. Stability  
Hypremellose powder is a stable material, although it is hygroscopic after drying. It 
should be stored in a well-closed container, in a cool, dry place. 
12. Safety 
Hypromelloseis generally regarded as a nontoxic and non-irritant material, although 
excessive oral consumption may have a laxative effect. 
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MICROCRYSTALLINE CELLULOSE
50 
1. Non- Proprietary Names 
BP : Microcrystalline cellulose 
JP  : Microcrystalline cellulose 
PhEur :Cellulosummicrocristallinum 
USP-NF : Microcrystalline cellulose 
2. Synonyms  
Avicel PH, celex, cellulose gel, celphere, ceolus KG, crystalline cellulose, E460, 
Emcocel, Ethispheres, Fibrocel, Pharmacel, Tabulose, Vivapur. 
3. Chemical Name 
     Cellulose  
4. CAS Registry Number 
       [9004-34-6] 
5. Empirical Formula 
     [C6H1005]n where n=220 
6. Molecular Weight  
      36000 
7. Functional Category 
 Adsorbent 
 Suspending agent 
 Tablet and capsule diluent 
 Tablet disintegrant 
8. Applications in Pharmaceutical Formulation 
 As a binder/diluents in oral tablet and capsule formulation in both wet- 
granulation and direct- compression process. 
 Its use as a binder/diluents, microcrystalline cellulose also has some lubricant and 
disintegrant properties that make it useful in tableting. 
 Microcrystalline cellulose is also used in cosmetics and food products. 
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9. Solubility  
     Slightly soluble in 5% w/v sodium hydroxide solution, practically insoluble in 
water, dilute axcids, and most organic solvents. 
10. Description  
     Microcrystalline cellulose is a purified, partially depolymerizerd cellulose that 
occurs as a white, odourless, tasteless, crystalline powder composed of porous 
particles. It is commercially available in different particle sizes and moisture grades 
that have different properties and applications. 
11. Incompatibilities 
      Cellulose acetate is incompatible with strongly acidic or alkaline substance. 
Cellulose acetate is compatible with the following plasticizers, diethyl phthalate, 
polyethylene glycol, triacetin, and triethyl citrate.  
12. Stability and storage conditions 
      Microcrystalline cellulose is a stable through hygroscopic material. The bulk 
material should be stored in a well- closed container in a cool, dry place. 
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MATERIALS USED 
To formulate the Ramipril Pulsincap, the following materials were obtained from 
manufacturers and used. 
Table 2: Drugs and Excipients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Drug/Exicipents 
Manufacturer/ 
Supplier 
Use in formulation 
1. Ramipril Vee care 
Active Pharmaceutical 
Ingredient 
2. HPMCK 4M MMC Health Care Hydrogel plug 
3. Egg Albumin Fisher Scientific Polymer 
4 
. 
Microcrystalline cellulose Pharma French Ltd Diluent 
5. PVPK30 Pharma French Ltd Binding agent 
6. Sodium starch glycolate Pharma French Ltd Super disintegrant 
7. Liquid paraffin Microfine Chemicals Dispersion Medium 
8. n-hexane Microfine Chemicals Solvent 
9. Span- 80 Orgochem Stabilizing agent 
10. Glutaraldehyde Merck Lab  Crosslinking agent 
11. Isopropyl alcohol Bafna , chennai Solvent  
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INSTRUMENTS AND EQUIPMENTS 
            To perform the formulation and analysis of Ramipril pulsatile drug delivery, 
the following instruments/equipments were utilized. 
                                                              Table 3: Instruments And Equipments 
S.No Instruments/ Equipments Manufacturer/ Suppliers 
1. Electronic Weighing Balance Asha scientific company, Mumbai. 
2. Magnetic Stirrer Remi Equipment  
3. Hot air oven MC Dalal, Chennai 
4. 8 Station compression machine Rimek, India 
5. pHmeter MC Dalal, Chennai 
6. Dissolution tester Veego, India 
7. Vernier Caliper Mitutoyo, Japan 
8. UV-visible spectrophotometer Shimadzu, Japan 
9. 
Fourier transform infra-red 
spectrophotometer 
Nicolet, India 
10. Microscope  
Sigma scientific instrumentation, 
Chennai. 
      
11. 
Scanning Electron Microscopy Hitachi 
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METHODOLOGY 
 
PREFORMULATION STUDIES
51
 
 Preformulation testing is the first step in the rationale development of dosage 
forms of a drug substance. It is defined as an investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients. The overall 
objective of preformulation testing is to generate information useful to the formulator 
in developing stable and bioavailable dosage forms, which can be mass-produced. 
 Following preformulation studies were preformed, 
1. Identification of Pure Drug 
  Identification of Ramipril was carried out by Infrared Spectroscopy. 
2. Drug-Excipient Compatibility Studies 
A successful formulation of a stable and effective solid dosage form depends 
on careful selection of excipients that are added to facilitate administration, promote 
the consistent release and bioavailability of the drug and protect it from degradation. If 
the excipients are new and not been used in formulation containing the active 
substance, the compatibility studies are of paramount importance.   
Compatibility of Ramipril with the respective polymers and excipients that is 
Egg albumin, sodium starch glycolate, microcrystalline cellulose, polyvinyl 
pyrollidone and the physical mixture of main formulation was established by infrared 
Absorption Spectra Analysis(FTIR). Any changes in the chemical composition after 
combining with the excipients were investigation with IR spectras. 
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ANALYTICAL METHODS
44,52
  
Standard Calibration Curve of Ramipril 
Calibration curve of Ramipril was prepared in three different buffers i.e. in 0.1N 
Hydrochloric acid, phosphate buffer pH 6.8 and phosphate buffer pH 7.4. 
Preparation of 0.1 N Hydrochloric acid 
0.1 N Hydrochloric acid was prepared by diluting 8.5 ml of concentrated Hydrochloric 
acid to 1000ml with distilled water. 
Preparation of Phosphate Buffer pH 6.8  
27.22 g of monobasic potassium phosphate was weighed and dissolved in 1000ml of 
distilled water to get stock solution of potassium phosphate. 8g sodium hydroxide was 
weighed and dissolved in 1000ml of distilled water to get 0.2M sodium hydroxide 
solution. 50ml of the monobasic potassium phosphate solution and 22.4 ml of sodium 
hydroxide solution were mixed and made up to 2000ml with distilled water. 
Preparation of Phosphate Buffer pH 7.4 
27.22g of monobasic potassium phosphate was weighed and dissolved in 1000ml of 
distilled water to get stock solution of monobasic potassium phosphate. 8g of sodium 
hydroxide was weighed and dissolved in 1000ml distilled water to get 0.2M sodium 
hydroxide solution.50ml of the monobasic potassium phosphate solution and 39.1ml 
of 0.2M sodium hydroxide solution were mixed and made upto 2000ml with distilled 
water. 
Calibration curve of Ramipril 
A stock solution was prepared by adding 10mg of drug in 100ml of0.1 N Hydrochloric 
acid,phosphate buffer pH6.8 and phosphate buffer pH 7.4 separately. The above 
solution was serially diluted with respective buffers to obtain solutionsin the 
concentration in the range of 10-50µg/ml. The absorbance of the samples was 
measured. 
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                      Preparation of Immediate Release Granules
53 
 
Table:4 Formulation of Immediate Release Granules 
S.No Ingredient G1(mg) G2(mg) G3(mg) G4(mg) 
1 Ramipril 500 500 500 500 
2 Sodium starch glycolate 86 178 272 386 
3 
Microcrystalline 
cellulose 
180 180 180 180 
4 PVP K30 3.6 3.6 3.6 3.6 
 
Granules of Ramipril were made by wet granulation method. Ramipril, Sodium starch 
glycolate, Microcrystalline cellulose were weighed accurately and blended 
homogeneously for 15 minutes. Polyvinyl pyrollidone was dissolved in isopropyl 
alcohol and mixed with the powder blend to get a coherent mass. The mass was 
passed through sieve no 22. 
EVALUATION OF GRANULES
 
Precompression Studies
20, 51 
1. Angle of Repose 
The angle of repose of blend was determined by the funnel method. The accurately 
weighted blend was taken in the funnel. The height of the funnel was adjusted in 
such a way that the tip of the funnel just touched the apex of the blend. The blend 
was allowed to flow through the funnel freely on to the surface. The diameter of the 
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powder cone was measured and angle of repose was calculated using the following 
equation. 
 tan Ø= h/r 
Where, h and r are the height of the powder cone. 
2. Bulk Density 
Density is defined as weight/unit volume. Bulk density is defined as the mass of the 
powder divided by the bulk volume and is expressed as g/cm
3 
.The bulk density of a 
powder primarily depends on particle size distribution, particle shape and tendency 
of particles to adhere together. Bulk density was determined by flowing powder into 
a graduated cylinder. The bulk volume and weight of the powder were determined 
.The bulk density was calculated using the following formula, 
                                  Bulk density = mass of the powder /bulk volume 
3. Tapped Density 
It is defined as the ratio of total mass of the powder to the tapped volume of the 
powder. Tapped density was determined by pouring gently a specified quantity of 
sample through a glass funnel into a 50ml graduated cylinder. The cylinder was 
tapped from a height of 2 inches until a constant volume was obtained. Tapped 
density was measured after 300 taps. Volume occupied by the sample after tapping 
was recorded and tapped density was calculated by the following formula, 
                              Tapped density =mass of the powder/tapped volume 
4. Carr’s  Compressibility Index (CI) 
Compressibility is the ability of the powder to decrease in volume under pressure. 
Compressibility is the measure that is obtained from density determinations. The CI 
was calculated using the formula,  
                CI = tapped density –bulk density / tapped density 100 
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5. Hausner’s Ratio (HR) 
It was determined by the ratio of tapped density to bulk density. It is calculated by 
the following formula,      
            HR= tapped density/bulk density 
                          Table:6 Angle Of Repose, Compressibility Index. Hausner’s Ratio 
 
 
 
 
 
 
 
 
 
 
 
6. Drug Content53 
 10mg granules were dissolved in a small quantity of methanol and the volume was 
made up to 100ml withphosphatae buffer pH 7.4. It was stirred for 12hrs. After 
stirring the solution was filtered through whatman filter paper and the absorbance 
was measured spectrophotometrically at 210nm after suitable dilution. 
 
 
Flow property 
Angle of 
repose 
Compressibility 
Index 
Hausner’s Ratio 
Excellent 25-30 10 1-1.1 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26-1.34 
Poor 46-55 26-31 1.35-1.45 
Very poor 56-55 32-37 1.46-1.59 
Very very poor >66 38 1.60 
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                   Preparation of Ramipril Albumin Microspheres
13 
                  Table: 5 Formulation of Microspheres 
S.No. Drug (mg) Polymer (mg) 
F1 500 500 
 F2 500 1000 
F3 500 1250 
F4 500 1500 
F5 500 2000 
 
                  Ramipril albumin microspheres were prepared by single emulsion 
polymerization technique. 100ml of liquid paraffin was taken in a beaker, mixed with 
0.4% w/v span 60, Stirred and heated at 70ºC. The mixture was cooled to room 
temperature. Drug and polymer were dissolved in methanol and phosphate buffer 
respectively and mixed together. This mixture was then poured drop wise to liquid 
paraffin using hypodermic syringe with continuous stirring at 600 Rpm and 0.25ml of 
glutaraldehyde was added. It was mixed for 3 hours. Microspheres were separated by 
decantation, washed 6 times with petroleum ether and dried at room temperature. The 
microspheres were stored in a dessicator. 
Preparation of Cross- Linked Gelatin Capsules
21
 
The “1” sized hard gelatin capsules about 100 in number were taken. The body of the 
capsules was placed on a wire mesh. 25ml of 15%v/v formaldehyde was taken into a 
desiccator and potassium permanganate was added to it to generate formalin vapours. 
The wire mesh along with the body was kept in the dessicator. The reaction was 
carried out for 12 hours, after which the body were removed and dried at 50ºC for 30 
minutes to ensure completion of reaction between gelatin and formaldehyde vapour. 
They were dried at room temperature to facilitate removal of residual formaldehyde. 
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Preparation of Hydrogel Plug 
Plug for sealing the capsule body was prepared by compressing HPMCK4M 
granules in polyvinyl pyrollidoneusing 9mm punches on rotary tablet press.  
Designing of Pulsincap 
The pulsincap was similar in appearance to a hard gelatin capsules, but the body was 
water insoluble. Microspheres equivalent to 2.5mg of Ramipril were accurately 
weighed and filled into the formaldehyde treated body. The capsules containing the 
microspheres were plugged with prepared hydrogel plug and capsule cap was filled 
with Ramipril granules equivalent to 2.5mg and placed over the body. 
EVALUATION OF MICROSPHERES 
36,40
 
1. Drug-Polymer interaction Study 
Interaction between drug-polymer was studied by InfraRed spectroscopy using 
FTIR spectrometer. Sample preparation involved mixing the sample with potassium 
bromide (KBr), triturating in glass mortar and finally placing in the sample holder. 
The spectrum was scanned over a frequency range of 4000-400cm
-1 
2. Particle Size Analysis 
The size was measured using an optical microscope and the mean particle size 
was calculated by measuring 100 particles with the help of a calibrated ocular 
micrometer. 
3. Angle of repose  
The angle of repose of blend was determined by the funnel method. The accurately 
weighted blend was taken in the funnel. The height of the funnel was adjusted in 
such a way that the tip of the funnel just touched the apex of the blend. The blend 
was allowed to flow through the funnel freely on to the surface. The diameter of the 
powder cone was measured and angle of repose was calculated using the following 
equation. 
 tan Ø= h/r 
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4. Drug content  
10mg drug loaded microspheres were dissolved in a small quantity of methanol and 
the volume was made up to 100ml with phosphatae buffer pH 7.4. It was stirred for 
12hrs. After stirring the solution was filtered through whatman filter paper and the 
absorbance was measured spectrophotometrically at 210nm after suitable dilution 
 
5. Drug Loading capacity 
Drug loading capacity was calculated by  
 Drug loading (%) = M actual / weighed quantity of powder of microspheres × 100 
Where M actual is the actual drug content in weighed quantity of powder of microspheres  
 
6. Percentage yield 
The prepared microspheres were collected and weighed. The yield was calculated by 
dividing the measured weight by the total weight of all non-volatile components. The 
percentage yield of microspheres was calculated as follows. 
 
                     % Yield =        Weight of microsphere        ×100 
                                        Theoretical weight of drug and polymer 
 
7. Scanning Electron Microscopy 
The samples were dried thoroughly in vacuum desiccators before mounting on 
brass specimen studies. The samples were mounted on specimen studies using double 
sided adhesive type, and gold palladium alloy of 120Aº knees was coated on the 
sample using sputter coating unit in Argon ambient of 8 – 10 Pascal with plasma 
voltage about 20MA. The sputtering was done for nearly 3mins to obtain uniform 
coating on the sample to enable good quality SEM images. The SEM was operated at 
low accelerating voltage of about 80MA. The condenser lens position was maintained 
between 4.4-5.1. 
MATERIALS AND METHODS 
 
Department of Pharmaceutics Page 60 
 
Physicochemical characterization of Hydrogel Plug
21
 
Hydrogel Plugs were studied for hardness, friability, weight variation, lag 
time and Swelling Index.    
Determination of Swelling Index of Hydrogel Plug 
Hydrogel plugs were kept immersed in three different pH conditions.  Plugs  
were  taken  out  carefully  at  2,4,6,8,10,12  hours    and    their  weights  were  
determined  accurately. 
 % Swelling = Wet weight − dry weight X 100  
                                   Wet weight     
Evaluation of cross linked Empty Capsules 
 Various physical and chemical tests were carried out for formaldehyde treated and 
untreated capsules
21
. 
Physical tests 
 Identification  
The capsules were observed physically. 
 Solubility Test for Formaldehyde Treated Capsules 
          The empty hard gelatin capsule was stirred vigorously in 100ml dissolution 
medium taken in 250ml beaker, with magnetic stirrer. Water, 0.1 N Hydrochloric 
acid1.2 pH, phosphate buffer pH 7.4 and phosphate buffer pH 6.8. The time at 
which the capsule dissolves or forms a soft mass was noted. 
 Dimension  
      Variation in dimension between formaldehyde treated and untreated capsules 
were studied. The length and diameter of capsules were measured before and after 
formaldehyde treatment, using caliper.  
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Chemical Test  
Qualitative Chemical Test for Free Formaldehyde 
7
 
     Formaldehyde solution (0.0002%w/v)was used as a standard solution. A 
sample solution was prepared by cutting 25 formaldehyde treated body of the 
capsules were cut into small pieces and placed in distilled water. This was stirred for 
1hr with a magnetic stirrer, to solubilize the free formaldehyde. The solution was then 
filtered into a 50ml volumetric flask, washed with distilled water and the volume 
made up with 50 ml with the washings. To 1ml of sample solution, 9ml of water was 
added. 1ml of the resulting solution was mixed with 4ml of water and 5ml of acetone. 
The solution was warmed in a water bath at 40ºc and allowed to stand for 4 minutes. 
INVITRO DISSOLUTION STUDIES 
a. For Ramipril Immediate release granules 
             The in vitro dissolution was carried out using USP Type I (Basket) 
dissolution apparatus under sink condition. The dissolution medium was 900 ml of a 
0.1N HCl solution (pH=1.2), at 37
0
C±0.2
0
C and the stirring speed of 50 rpm. The in 
vitro release studies were carried out for 2 hours.10ml of sample was taken at 10 
minutes intervals for 2 hours and were replaced with fresh dissolution medium. The 
absorbance of the solution was recorded at 210 nm using UV spectrophotometer. 
b. For Ramipril Microspheres 
               The in vitro dissolution was carried out using USP Type I (Basket) 
dissolution apparatus under sink condition. The dissolution medium was 900 ml of a 
phosphate buffer pH 6.8 at 37
0
C±0.2
0
C and the rotating speed was 50 rpm. 10ml of 
sample was taken at 1hour intervals for subsequent hours and were replaced with 
fresh dissolution medium. The absorbance of the solution was recorded at 210 nm 
using UV spectrophotometer. 
 
 
MATERIALS AND METHODS 
 
Department of Pharmaceutics Page 62 
 
c. In Vitro Release of Pulsatile Capsule21 
Dissolution studies were carried out using USP XXIII dissolution test apparatus 
(paddle method).  Capsule was tied to paddle with a cotton thread so that the capsule was 
immersed completely in dissolution media but not float. In order to simulate the pH 
changes along the GI tract, three dissolution media with pH 1.2, 7.4 and 6.8 were 
sequentially used,(sequential pH change method). The  pH  1.2 was  first  used  for  2  hrs 
then  removed  and  the  fresh phosphate buffer pH  7.4was added. After 3 hrs the 
medium was removed  and  colonic  fluid   phosphate buffer pH  6.8 was  added  for  
subsequent study.  Nine hundred milliliters of the dissolution medium was used at each 
time.  Rotation speed  was  100  rpm  and  temperature  was  maintained  at 37±0.5 ten 
millilitres of dissolution medium was withdrawn at predetermined time intervals and 
fresh dissolution media  was  replaced.  The withdrawn samples were analysed at 210 
nm, by UV absorption spectroscopy and the cumulative percentage release was 
calculated. 
KINETIC ANALYSIS OF RAMIPRILIN VITRO RELEASE DATA
40 
 The in vitro drug release data were tested with the following mathematical model. 
The goodness of fit was found out to describe the kinetics of drug release. 
Zero Order Release Model 
 Zero order models describe the systems where the drug release rate is independent 
of its concentration. The equation assumes that the cumulative amount of drug 
release is directly related to time. 
     C=k0t 
 Where, 
  C – Cumulative percentage drug release 
  K0 – Zero order rate constant expressed in unit concentration/time 
  t- Time in hour 
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 A graph of concentration vs time would yield a straight line with a slope equal to 
k0 and intercept the origin of x axis. 
First Order Release Model 
 First order models describe the systems where the release rate is dependent on the 
concentration. The release behavior of first order equation is expressed as log 
cumulative percentage of drug remaining vs time. The equation as follows, 
Log C = log Co – kt / 2.303 
Where, 
 C- Cumulative percentage drug remaining 
 Co – Initial concentration of drug 
            K – First order constant 
A plot of time on x-axis and log cumulative percentage drug remaining on 
y-axis gives a straight line with slope, k/2.303 if it follows first-order kinetics. 
Higuchi Square Root Law Model 
The Higuchi model describes the release from systems where the solid drug 
is dispersed in an insoluble matrix and the rate of release is related to the rate of 
drug diffusion. This model describes the cumulative percentage of drug release vs 
square root of time. The equation is as follows, 
Q = kt
1/2
 
Where, 
 Q – Cumulative percentage drug released 
 K – Constant reflecting the design variables of the system 
 T – Time 
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A plot of square root of time on x-axis and cumulative percentage drug 
released on y-axis gives a straight line if it follows Higuchi Kinetics. 
 
Hixson-Crowell Release Model 
The Hixson-Crowell cube root model describes the release from systems 
where there is a change in surface area and diameter of the tablets or particles. 
Q0
1/3
 – Qt
1/3
 = K HC t 
Where, 
Qt - Cumulative percentage drug released in time t, 
Q0 -Initial amount of drug 
KHC -Rate constant of Hixson-Crowell equation 
A plot of time on x-axis and cube root of cumulative percentage of drug 
remaining on y-axis gives a straight line if it follows Hixson-Crowell kinetics. 
Korsmeyer and Peppas Model 
Korsmeyer and Peppas Model derive a simple relationship which describes 
the drug release from a polymeric system equation. 
Mt / M = K t 
n
 
Where, 
 Mt/M  - Fraction of drug released at time t 
 k- Release rate constant 
 n - Release exponent  
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A plot of log time on x-axis and log cumulative percentage of drug released 
on y-axis gives a straight line if it follows Korsmeyer and Peppas kinetics. The n 
value is used to characterize different release mechanism. 
Table: 7 Diffusion Exponent and Solute Release Mechanism for        
Cylindrical Shape 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45 <n<0.89 Anamolous (non-Fickian) diffusion 
0.89 Case – II transport 
n>0.89 Super case – II transport 
  
STABILITY STUDIES
54 
Stability of a drug has been defined as the ability of a particular formulation, in 
a specific container, to remain within its physical, chemical, therapeutic, and 
toxicological specifications. The purpose of stability testing is to provide evidence on 
how the quality of a drug substance or drug product varies with time under the 
influence of a variety of environmental factors such as temperature, humidity, and light 
and enables recommended storage conditions, re-test periods and shelf lives to be 
established. The optimized formulation was selected and the stability study was carried 
out at accelerated condition of 40C / 75% RH condition for a period of 3 months. 
Method 
Optimized formulation were packed in blister and stored in stability chambers 
maintained at 40C / 75% RH for three months. After 3 months samples were analyzed 
for physical appearance, drug content and in vitro release.  
  
 
 
 
 
RESULTS AND 
DISCUSSION 
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                               RESULTS AND DISCUSSION 
DRUG-EXCIPIENT COMPATIBILITY STUDY 
The drug-excipient compatibility study was conducted to reveal the excipient 
compatibility with the drug.  
Physical Compatibility Study: The physical compatibility of drug and excipients 
were given in Table 8. 
Table 8: Physical Compatibility Study of Drug and Excipients 
NC- No Change 
S.No. 
 
Drug + Excipient 
Description and Condition 
Initial 
Room 
Temperature  and 
40
0
C/ 75% RH in 
Days 
10
th
 20
th
 30
th
 
1 RAMIPRIL White, almost white crystalline powder NC NC NC 
2 EGG ALBUMIN Yellow powder NC NC NC 
3 HPMC K4M White or creamy white crystalline powder NC NC NC 
4 MCC White, crystalline powder NC NC NC 
5 PVPK30 
White or Creamy white colored 
Hygroscopic Powder 
NC NC NC 
6 SSG Creamy white Free flowing fine powder NC NC NC 
7 
RAMIPRIL +EGG 
ALBUMIN 
White, yellow colored powder NC NC NC 
8 
RAMIPRIL + 
HPMC K4M 
White or creamy white coloured powder NC NC NC 
9 RAMIPRIL +MCC White, crystalline powder NC NC NC 
10 
RAMIPRIL +PVP 
K30 
White, crystalline powder NC NC NC 
11 RAMIPRIL + SSG White or off white  crystalline powder NC NC NC 
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The physical compatibility study was performed visually. The study implies 
that the drug and excipients were physically compatible with each other as there was 
no change of physical description. The excipients which were compatible with the 
drug were selected for formulation. 
Chemical Compatibility Study (FTIR) 
FTIR spectroscopy was carried out to study the compatibility of pure drug 
ramipril with the polymer albumin, and other excipients like microcrystalline 
cellulose, sodium starch glycolate, polyvinylpyrrolidone, hydroxyl propyl 
methylcellulose. 
                      
Figure 4. FTIR Spectra of Ramipril 
                                   Table 9. IR Interpretation of Ramipril 
 
 
 
 
Wave Number (cm
-1
) Interpretation 
3672.20 OH stretching 
3463.90 NH stretching 
2869.87 CH stretching 
1743.52 C=O ACID stretching 
1650.95 C=O ESTER stretching 
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Figure5: IR of Egg Albumin 
Table No :10 IR Interpretation of Egg Albumin 
 
 
 
 
 
 
 
 
 
 
 
Wave length cm
-1 
 
Interpretation 
3423.18 
 
O – H  stretching 
2961.91 
 
C – H  stretching 
2925.32 
 
C – H  stretching 
2849.59 
 
C – H  stretching 
1654.18 
 
C = N  stretching 
1560.01 
 
C = O stretching 
1541.67 
 
C = O stretching 
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Figure6: FTIR of Ramipril and Egg Albumin 
 
Table No :11 IR Interpretation of Egg Albumin and Ramipril 
 
 
 
 
 
 
 
 
There is no appearance or disappearance of any characteristic peaks. This shows that there is no 
chemical interaction between the Ramipril and Egg Albumin 
Wave length cm
-1 
 
Interpretation 
3423.18 
 
O – H  stretching 
2961.91 
 
C – H  stretching 
2925.32 
 
C – H  stretching 
2849.59 
 
C – H  stretching 
1654.18 
 
C = N  stretching 
1560.01 
 
C = O stretching 
1541.67 
 
C = O stretching 
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Figure 7. FTIR Spectra of Ramipril and PVP 
 
Table 12. IR Interpretation of Ramipril and PVP 
 
 
 
 
 
 
 
 
There is no appearance or disappearance of any characteristic peaks. This shows that there is no 
chemical interaction between the Ramipril and PVP. 
Wave Number (cm
-1
) Interpretation 
3885.92 OH stretching 
3456.18 NH stretching 
2869.30 CH stretching 
1743.52 C=O ACID stretching 
1650.95 C=O ESTER stretching 
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                           Figure 8. FTIR Spectra of Ramipril and MCC 
 
                 Table 13. IR Interpretation of Ramipril and MCC 
Wave Number (cm
-1
) Interpretation 
3741.63 OH stretching 
3348.18 NH stretching 
2869.87 CH stretching 
1743.52 C=O ACID stretching 
1650.95 C=O ESTER stretching 
 
There is no appearance or disappearance of any characteristic peaks. This shows that there is no 
chemical interaction between the Ramipril and MCC. 
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               Figure 9. FTIR Spectra of Ramipril and SSG 
                      Table 14. IR Interpretation of Ramipril and SSG 
Wave Number (cm
-1
) Interpretation 
3795.63 OH stretching 
3440.76 NH stretching 
2923.87 CH stretching 
1820.67 C=OACID stretching 
1743.52 C=O ESTER stretching 
 
There is no appearance or disappearance of any characteristic peaks. This shows that there is no 
chemical interaction between the Ramipril and SSG. 
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Figure 10. FTIR Spectra of Ramipril and HPMCK4M 
 
Table 15. IR Interpretation of Ramipril and HPMCK4M 
Wave Number (cm
-1
) Interpretation 
3733.91 OH stretching 
3417.61 NH stretching 
2923.87 CH stretching 
1650.95 C=OACID stretching 
1743.52 C=O ESTER stretching 
  
There is no appearance or disappearance of any characteristic peaks. This shows that there is no 
chemical interaction between the Ramipril and HPMCK4M. 
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CALIBRATION CURVE OF RAMIPRIL 
The absorbance of the drug in various buffers, 0.1N Hydrochloric acid 
pH1.2, phosphate buffer pH 7.4 and phosphate buffer pH 6.8 was measured at a 
wavelength of 210nm. The results are given in table 16.  
Table 16. Data for standard curve of Ramipil 
S.No 
Concentration 
(mcg/ml) 
Absorbance at 210 nm 
pH 1.2 pH 7.4 pH 6.8 
1. 10 0.210 0.455 0.254 
2. 20 0.398 0.576 0.476 
3. 30 0.610 0.688 0.660 
4. 40 0.810 0.803 0.887 
5. 50 1.05 0.917 1.140 
 
                          
            Figure 11. Standard Curve of Ramipril in 0.1 N HCL pH 1.2 
y = 0.0207x - 0.0057 
R² = 0.9989 
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                      Figure 12. Standard curve of Ramipril in Phosphate Buffer pH 7.4 
 
 
                       
 
Figure 13. Standard Curve of Ramipril in Phosphate Buffer pH 6.8  
The standard curve is linear in the concentration range 0 to 50 mcg/mland starts from the origin. 
It obeys Beer Lambert‘slaw.  
y = 0.0212x - 0.003 
R² = 0.9991 
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PRECOMPRESSION STUDIES OF THE PREPARED MICROSPHERES 
AND GRANULES 
The precompression parameters for the microsphere and granules are given in table 17, 
18. 
Table 17.Precompression Parameters of Microspheres 
Properties 
 
Drug 
M1 M2 M3 M4 M5 
Angle of 
repose (θ) 
 
42.15±0.267 
 
33.37±0.2011 
33.3±0.7028 33.88±0.4929 34.34±0.3546 33.0±0.3750 
Bulk 
density 
(g/ml) 
 
1.20±0.0967 
 
0.666±0.00707 
0.6±0.005657 
 
0.625±0.007542 
 
0.666±0.007071 
 
0.7±0.009428 
Tapped 
density 
(g/ml) 
 
1.57±0.0989 
 
0.75±0.08957 
 
0.666±0.007071 
 
0.714±0.009899 
0.75±0.00948 0.8±0.01084 
Carr’s 
index (%) 
 
23.56±0.9969 
11.2±0.988 9.90±0.9076 12.46±0.5666 11.2±0.8485 12.5±0.2854 
Hausner’s 
ratio 
1.30±0.0998 
1.136±0.01053 1.11±0.00282 1.142±0.01517 1.126±0.02248 1.142±0.02248 
 
Mean ±SD(n=3) 
The flow property of pure drug was found to be passable and it was identified good flow 
property for prepared Ramipril microspheres. 
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Table 18.Precompression Parameters for Granules 
 
Properties G1 G2 G3 G4 
Angle of 
repose (θ) 
34.48±0.0023 33.0±0.0012 34.62±0.0045 33.88±0.0056 
Bulk 
density 
(g/ml) 
0.443±0.0124 0.485±0.0108 0.443±0.01699 0.456±0.01699 
Tapped 
density 
(g/ml) 
0.552±0.0740 0.582±0.01766 0.521±0.0201 0.539±0.0335 
Carr’s 
index (%) 
18.63±0.008 16.67±0.0235 15.00±0.0162 15.31±0.0202 
Hausner’s 
ratio 
1.239±0.0128 1.2±0.03536 1.174±0.02166 1.177±0.02577 
 
                       Mean SD (n=3) 
 
The flow property of granules was found to be good. 
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Drug content  
Drug content of Ramipril granules was analyzed using UV spectrophotometer at 
210nm. 
                             Table 19: Drug Content Of Granules 
Formulation % Drug content 
G1 94 
G2 96 
G3 92 
G4 98 
 
The drug content of prepared granules was found to be with in pharmacopeial      
limits. 
Scanning Electron Microscopy 
  
 
 
 
 
 
 
 
Figure 14. Scanning Electron Microscopy of M4  
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PERCENTAGE YIELD 
Table 20. % Yield of Ramipril Microspheres 
Formulation 
code 
Theoretical yield (gm) 
Practical yield 
(gm) 
Percentage yield 
(%) 
M1 1 0.87 87 
M2 1.5 1.354 90 
M3 1.75 1.674 95.65 
M4 2 1.983 99.15 
M5 2.5 2.451 98.07 
 
              After the preparation of microspheres practical yield and percentage yield were 
calculated. The percentage yield was in the range of 87% to 98.07%w/w. 
DRUG CONTENT AND LOADING CAPACITY 
Table 21. Drug Content and Loading Capacity 
Formulation 
code 
Drug content (%) w/w Drug Loading (%) 
M1 84.4% 11.5% 
M2 81.2% 18.6% 
M3 83.2% 23.77% 
M4 86.3% 35.04% 
M5 76.04% 25.09% 
 
         The drug content of microspheres ranged from 76.04 to 86.3 % w/w. 
Formulation M4 contained the maximum drug content. 
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Evaluation of cross linked empty capsules 
Physical Tests 
 Identification  
 
The ‘1’ size capsules were with purple cap and colourless body. They were 
lockable type, odorless, softy and sticky when treated with wet fingers. After 
formaldehyde treatment, there were no significant changes in the capsules. They 
were non-tacky when touched with wet fingers. 
 
 Chemical Test  
 
Qualitative Chemical Test For Free Formaldehyde  
The solution was not more intensely coloured then a reference solution prepared 
at the same time and in the same manner using 1 ml of standard solution. The colour of 
the test and standard solutions were compared. 
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PARTICLE SIZE DISTRIBUTION  
Table 22.Particle Size Distribution of Formulation M1 
Range Mean Size 
No. of particles 
(n) 
nd % Frequency 
10–20 15 0 0 0 
20-30 25 4 100 4 
30-40 35 0 0 0 
40-50 45 11 495 11 
50-60 55 19 1045 19 
60-70 65 10 650 10 
70-80 75 11 825 11 
80-90 85 20 1700 20 
90-100 95 25 2375 25 
    n=100   nd=7190       Σ=nd/n =71.9µm 
 
 
 
 
 
 
 
                        Figure 15. Particle Size Distribution of Formulation M1 
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The average particle size of M1 was found to be 71.9µm 
Table 23.Particle Size Distribution of Formulation M2 
Range Mean Size 
No. of particles 
(n) 
nd % Frequency 
10–20 15 3 45 3 
20-30 25 0 0 0 
30-40 35 4 140 4 
40-50 45 9 405 9 
50-60 55 20 1100 20 
60-70 65 9 585 9 
70-80 75 10 750 10 
80-90 85 19 1615 19 
90-100 95 26 2470 26 
           n=100  nd=7010     Σ=n/nd=70.10µm 
                       
Figure 16. Particle Size Distribution of Formulation M2 
                              The average particle size of M2 was found to be 70.10µm. 
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                               Table 24. Particle Size Distribution of Formulation M3 
    n=100             nd=7220         Σ=n/nd=72.2µm 
                  
              Figure 17. Particle Size Distribution of Formulation M3 
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Range µm 
Range  Mean size No.of particles (n) n×d % Frequency 
10–20 15 2 30 2 
20-30 25 0 0 0 
30-40 35 3 105 3 
40-50 45 9 405 9 
50-60 55 19 1045 19 
60-70 65 11 715 11 
70-80 75 10 750 10 
80-90 85 20 1700 20 
90-100 95 26 2470 26 
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              The average particle of M3 was found to be 72.20µm 
 Table 25. Particle Size Distribution of Formulation M4 
Range Mean Size 
No. of particles 
(n) 
nd % Frequency 
10–20 15 0 0 0 
20-30 25 4 100 4 
30-40 35 2 70 2 
40-50 45 2 90 2 
50-60 55 25 1375 25 
60-70 65 20 1300 20 
70-80 75 10 750 10 
80-90 85 17          1445 17 
90-100 95 20 1900 20 
    n=100         nd=7030     Σ=n/nd=70.30µm 
                        
                                Figure 17. Particle Size Distribution of Formulation M4 
                             The average particle size of M3 was found to be 70.30µm. 
0
5
10
15
20
25
30
10 20 30 40 50 60 70 80 90
F
re
q
u
en
cy
 (
%
) 
Range µm 
RESULT & DISSCUSION 
 
Department of Pharmaceutics Page 85 
 
 
Table 26. Particle Size Distribution of Formulation M5 
 
Range 
 
Mean Size 
No. of particles 
(n) 
nd % Frequency 
 
10–20 15 2 30 2 
 
20-30 
25 0 0 0 
 
30-40 35 6 210 6 
 
40-50 
45 8 360 8 
 
50-60 
55 19 1045 19 
 
60-70 
65 10 650 10 
 
70-80 75 12 900 12 
 
80-90 
85 21 1785 21 
 
90-100 95 22 2090 22 
    n=100  nd=7070     Σ=n/nd=70.70µm 
                                 
              Figure 19. Particle Size Distribution of Formulation M5 
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               The average particle size of M5 was found to be 70.70µm. 
 
             EVALUATION PARAMETERS FOR HYDROGEL PLUG 
                                        Table.27 Evaluation Of Hydrogel Plug 
Hydrogel plug 
code  
Weight (mg) Thickness (mm) Hardness  
P1 100mg 3.20 ±0.0023 2.4 ±0.0056 
 Table. 28 Swelling index 
pH Time(Hrs) % Swelling index 
 
 
 
pH 1.2 
2 33.11 
4 52.38 
6 64.82 
8 70.29 
10 72.22 
12 75.48 
 
 
pH 7.4 
2 37.65 
4 54.09 
6 65.03 
8 70.88 
10 72.58 
12 75.77 
 
 
pH 6.8 
2 37.26 
4 53.66 
6 64.70 
8 70.97 
10 73.04 
12 76.07 
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                    Figure 20. Swelling index in 0.1 N HCL 
 
 
                              
                     Figure 21. Swelling index in phosphate buffer pH 7.4 
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                   Figure 22. Swelling index in phosphate buffer pH 6.8 
 
Swelling index of HPMCK4M hydrogel plug showed the plug integrity and 
increased swelling during the study.  
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
2 4 6 8 10 12
Time in Hours 
%
 s
w
e
lli
n
g 
 
RESULT & DISSCUSION 
 
Department of Pharmaceutics Page 89 
 
 
                         TABLE 29.IN VITRO DISSOLUTION OF RAMIPRIL IR   
 
Time in 
minutes 
 
Cumulative % drug release  
 
G-1 
 
 
G-2 
 
G-3 
 
G-4 
10 30.6±0.236 34.88±0.442 38.87±0.447 38.52±0.132 
20 36.68±0.583 73.15±0.246 79.18±0.242 72.84±0.612 
30 61.6±0.134 87.64±0.463 94.56±0.293 101.59±0.413 
40 75.88±.123 92.2±0.674 101.67±0.473  
50 90.07±.314 102.68±0.349   
60 101.78±0.213    
    Mean SD (n=3) 
                            
                 Figure 23.In vitro dissolution of Ramipril IR 
The in vitro dissolution of Ramipril IR showed that G4 was found to be optimum 
for immediate release. 
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                   TABLE 30. IN VITRO DISSOLUTION OF RAMIPRIL MICROSPHERES 
 
Time 
in 
Hours 
 
Cumulative % drug release  
 
M-1 
 
 
M-2 
 
M-3 
 
      M-4 
 
     M-5 
1 11.2±0.098 9.76±0.586 8.26±0.098 4.56±0.067 10.62±0.023 
2 16.68±0.167 15.08±0.235 11.72±0.076 10.11±0.0789 15.2±0.197 
3 36.28±0.056 31.72±0.067 29.69±0.309 14.86±0.543 25.59±0.942 
4 44.6±0.087 41.12±0.054 36.12±0.209 23.91±0.0721 37.39±0.621 
6 58.02±0.065 48.52±0.452 42.12±0.120 34.9±0.129 44.62±0.185 
8 69.2±0.128 56.32±0.234 51.47±0.521 45.16±0.284 54.32±0.049 
10 74.12±0.112 67.72±0.601 60.27±0.045 52.16±0.492 67.21±0.183 
12 89.76±0.078 79.6±0.067 72.71±0.098 61.01±0.719 79.14±0.061 
14 99.21±0.478 86.12±0.087 81.92±0.067 74.21±0.497 87.56±0.674 
16  99.92±0.012 91.99±0.390 88.41±0.045 97.26±0.184 
18   101.77±0.865 92.76±0.729 101.08±0.295 
19    101.02±0.571  
      
 
   Mean SD (n=3) 
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Figure 24.In vitro dissolution of Ramipril IR  
 
                         
 
 
 
The invitro release of Ramipril microspheres was evaluated. M4 have more sustained 
release than all the formulations therefore M4 was optimized.  
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                 TABLE 31.IN VITRO RELEASE OF RAMIPRIL PULSINCAP 
Dissolution Medium Time % Cumulative Drug 
Release 
0.1N HCL pH 1.2 Buffer 10 
20 
30 
40 
50 
60 
90 
120 
3 
4 
5 
6 
7 
19 
20 
21 
22 
23 
24 
18.84±0.169 
36.47±0.278 
50.67±0.061 
51.26±0.037 
51.82±0.028 
51.51±0.069 
53.03±0.119 
53.67±0.043 
0 
0 
0 
4.95±0.042 
6.74±0.016 
32.50±0.075 
38.61±0.113 
41.45±0.0478 
45.46±0.171 
48.41±0.004 
50.30±0.063 
pH 7.4 Buffer 
pH 6.8 Buffer 
 
   Mean SD (n=3) 
 
 
RESULT & DISSCUSION 
 
Department of Pharmaceutics Page 93 
 
 
                                  Figure 25.In vitro release of Ramipril Pulsincap 
                              
                                       Table 30. Release Kinetics of Ramipril Pulsincap 
Time 
(Hrs) 
Log 
Time 
(Hrs) 
Sq.root of 
time (Hrs) 
Cum % 
drug 
release 
Cum% 
drug 
remaining 
Log Cum 
% drug 
release 
Log cum 
% drug 
remaining 
Cube root 
of cum % 
drug 
remaining 
0 -∞ 0 0 50 -∞ 1.698 3.68 
6 0.778 2.449 4.98 45.02 0.697 1.653 3.557 
7 0.845 2.645 6.76 43.24 0.829 1.635 3.509 
19 1.278 4.358 32.06 17.44 1.512 1.241 2.593 
20 1.301 4.472 38.77 11.23 1.588 1.050 2.239 
21 1.322 4.582 41.43 8.57 1.614 0.932 2.046 
22 1.342 4.690 45.26 4.74 1.655 0.675 1.679 
23 1.361 4.795 48.14 1.86 1.682 0.269 1.229 
24 1.380 4.898 50.24 0.24 1.701 0.619 0.621 
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Figure 26 : A Plot Of Zero Order Kinetics 
 
 
                          
 
                                          Figure 27 : A Plot First Order Kinetics 
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                                      Figure 28: A Plot Higuchi Release Kinetics 
 
 
                       
                                      Figure 29: A PlotHixson- Crowell Kinetics 
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                                Figure 30: A Plot Korsemeyer-Peppas  Kinetics 
 
Determination of drug release mechanism of optimized Ramipril Pulsincap 
 The order of release was found to be zero order in which R2 value was close to 1 . So the 
formulation follows zero order kinetics followed by Korsemeyer-peppas model. 
 The mechanism of drug release was found to be diffusion and dissolution.  
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Stability study: 
The optimized pulsincap were subjected to stability studies and the results are given in 
Table 31. 
Table 31: Drug content and Dissolution profile of Ramipril 
Time interval 
(month) 
Drug content (%) Cumulative % release 
Immediate 
release 
Granules  
Microspheres  Immediate 
release 
Granules 
Microspheres 
1 month 98.70±0.016 86.53±0.021 53.45±0.044 51.70±0.148 
2 month 98.99±0.022 86.73±0.036 52.99±0.054 51.31±0.048 
3 month 97.23±0.033 85.01±0.024 53.53±0.014 51.20±0.014 
Mean ±SD (n=3) 
No significant changes were observed in the physical appearance, colour, drug content 
and drug release of Ramipril pulsincap of the optimized batch at 40
0
C /75% RH. The Ramipril 
pulsincap are stable. 
 
 
 
 
 
 
 
  
 
 
 
 
 
SUMMARY AND 
CONCLUSION 
 
 
 
SUMMARY AND CONCLUSION 
 
SUMMARY AND CONCLUSION 
Ramipril is an antihypertensive drug belongs to the class of angiotensin converting 
enzyme inhibitor (ACE).It has relatively poor pharmacokinetic profile with 28-35% absolute 
bioavailability undergoing extensive first pass metabolism. It has half life of 2-4hrs. To 
overcome these drawbacks and to release the drug in a sustained manner, Ramipril was 
formulated as microspheres by Emulsion polymerization technique using Egg Albumin as 
polymer .The immediate release was prepared as granules by wet granulation method. 
 Preformulation studies were performed for microspheres and granules. The flow 
properties were found to be good. 
 Physical compatibility study showed that the drug and excipient were physically 
compatible with each other. 
 Chemical compatibility study using FTIR spectroscopy revealed no interaction between 
the drug and excipients. 
 The  capsule body was  made insoluble by formaldehyde  treatment  and  were  subjected  
to  various  physical  and chemical  test  such  as  dimension  measurement,  solubility  
studies  and  qualitative for free formaldehyde.  
 Hydrogel plug was prepared with 9mm punch and post compression study was 
performed. 
 The size of microspheres was confirmed by SEM.  
 The in vitro release studies were preformed for all the formulations. G – 4 showed 101.59 
% at 30 minutes , M – 4 showed 101.02% at the end of 19th hour. Therefore it was chosen 
as the optimized formulation for pulsincap.  
 The invitro release of pulsincap for optimized formulation were performed.  
 The accelerated stability testing was carried out for 3 months and was found to be stable. 
 FUTURE SCOPE 
 In -vivo study using gamma scintillography method 
 Pharmacokinetic and toxicity study 
 Stability studies-long term 
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